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Policy context 
Cardiovascular disease (CVD) is highly preventable. CVD continues to be the largest contributor to mortality 
within the Aboriginal and Torres Strait Islander population and rates of CVD are disproportionately higher 
within the Australian Aboriginal and Torres Strait Islander population compared to the non-Indigenous 
population. Improving uptake of current evidence based solutions such as the absolute risk approach to CVD 
within the Aboriginal and Torres Strait Islander population is important to address this disparity. Although 
there are several tools available supporting an absolute CVD risk approach, clinical uptake is limited due to a 
number of factors including an outdated continued reliance on the ‘single risk factor’ approach to prevention, 
diagnosis and treatment of CVD. A major barrier to uptake is inconsistent messages in the current clinical 
practice guidelines. 
Key messages 
 There are three main guidelines on the absolute CVD risk approach for Aboriginal and Torres Strait 
Islander peoples in Australia: The NVDPA Guidelines for the Management of Absolute Cardiovascular 
Disease Risk; The Central Australian Rural Practitioners Association Standard Treatment Manual; and 
the RACGP National Guide to a Preventive Health Assessment for Aboriginal and Torres Strait Islander 
People.  
 There is considerable alignment between the existing guidelines, including the need for an absolute 
risk approach, conditions conferring automatic high risk, use of the Framingham risk equation as the 
basis of calculating absolute risk, and the need to treat people at a greater than 15% risk of a primary 
CVD event over the next five years. 
 The guidelines diverge materially in relation to four recommendations: 
o the age at which to commence absolute CVD risk assessment; 
o whether or not calculated risk scores should be adjusted upward by 5%;  
o how often CVD risk should be assessed; and  
o treatment targets for blood pressure. 
 Available evidence indicates that CVD events and high absolute CVD risk occurs earlier in Aboriginal 
and Torres Strait Islander peoples, and that prevention of CVD should also start early. The proportion 
of Aboriginal and Torres Strait Islander peoples at high absolute CVD risk at the ages of 18-34 years 
broadly corresponds to the proportion at high risk among the general population aged 45-54 years.  
 Limited evidence suggests that the current risk scores are likely to underestimate risk in Aboriginal 
and Torres Strait Islander peoples. Specific data on the extent of underestimation and alternative 
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validated risk scores in this population are lacking. There is no primary data on adjusting risk scores 
upwards by 5% in Aboriginal and Torres Strait Islander people.  
 Frequency of CVD risk assessment should be based on initial level of risk but the optimal interval for 
risk reassessment at each level of risk is not clear.   
 There is general agreement between the guidelines to lower blood pressure as tolerated but there are 
inconsistencies in the exact blood pressure target. Evidence suggests that reductions in systolic blood 
pressure result in proportional reductions in CVD events and all-cause mortality. 
 CVD guidelines could be kept up to date by adopting a ‘living’ guidelines model, but consideration 
needs to be given to how to identify relevant updated evidence and how to integrate the updates into 
electronic decision support tools.
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Background 
T h e  i m p a c t s  o f  C V D  
Cardiovascular disease (CVD) is the leading cause of death globally and is a major contributor to 
morbidity. CVD is largely preventable, through effective evidence-based population- and individual-
level interventions. There are high rates of premature Aboriginal and Torres Strait Islander CVD in 
Australia. Hospitalisation rates for ischaemic heart disease between the ages of 25 and 44 are 7-8 times 
higher among Aboriginal and Torres Strait Islander Australians compared to non-Indigenous Australians 
and 52% of Aboriginal and Torres Strait Islander CVD hospital admissions are among those aged <55 
years, compared to 17% for non-Indigenous Australians.1 Increased exposure to CVD risk factors, 
including smoking, diabetes and high blood pressure, rather than ethnicity per se, among these 
populations are primarily responsible for increased CVD risk.1 
 
E v i d e n c e  b a s e d  a p p r o a c h  t o  C V D  r i s k  a s s e s s m e n t  
Australian and international guidelines for CVD prevention and treatment recommend assessment and 
management of CVD risk using an absolute risk approach, that integrates information from multiple 
risk factors to assess how likely someone is to develop CVD in a given time period.2-5 The use of multiple 
risk factors is highly predictive, and this approach is considered cost-effective and minimises under- 
and over-treatment compared to an approach using single risk factors.6 In Australia, a person’s risk of 
a primary CVD event (including heart attack and stroke) over the next five years is assessed using risk 
calculators and charts, combining clinical risk factors and the Framingham Risk Equation (FRE). The 
2008 FRE uses information from the main CVD risk factors that can be easily assessed in primary care 
including age, total cholesterol, high-density lipoprotein (HDL) cholesterol, systolic blood pressure, 
smoking status and diabetes status.7 In Australia, people classified as having an absolute risk above 15% 
in the next five years from the FRE are classified as being at high risk of a primary CVD event. In addition, 
certain groups can be assumed to be at high risk of cardiovascular events because of a diagnosed 
clinical condition and a calculation of absolute CVD risk in these people is not considered necessary. 
This includes those with prior CVD and those with specific clinical risk factors such as moderate or 
severe chronic kidney disease and diabetes with microalbuminuria.  
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A b o r i g i n a l  a n d  T o r r e s  S t r a i t  I s l a n d e r  a b s o l u t e  C V D  r i s k  
Nationally-representative data from the 2012-13 National Aboriginal and Torres Strait Islander Health 
Measures Survey show that among people aged 35-74 years, 10% had prior CVD and 16% were 
estimated to be at high absolute risk of a primary CVD event using the NVDPA absolute CVD risk 
assessment algorithm.8 Around half of those at high risk of a future CVD event were not receiving lipid-
lowering medications (47% for those with prior CVD and 58% for those at high risk of a primary CVD 
event).8 In comparison, an estimated 20% of Australians between the ages of 45 and 74 are considered 
to be at high risk of a future CVD event (this includes 9% with prior CVD and 11% with high risk of a 
first-time primary event) with over two-thirds not receiving preventative treatments of combined 
blood pressure- and lipid-lowering medications.9 
  
Aboriginal and Torres Strait Islander CVD risk is influenced by social and cultural determinants. 
Determinants that are specific to Aboriginal and Torres Strait Islander peoples include intergenerational 
trauma resulting from the effects of colonisation, loss of land and the erosion of cultural and spiritual 
identity10 and racism and discrimination.11 These determinants can directly impact on Aboriginal and 
Torres Strait Islander peoples’ social and emotional wellbeing and contribute to an increase in 
behavioural and physiological risk factors, such as smoking and body mass index, thereby increasing 
the risk of CVD.12-14 
 
U p t a k e  o f  t h e  a b s o l u t e  C V D  r i s k  a s s e s s m e n t  a n d  m a n a g e m e n t  
a p p r o a c h  i n  A u s t r a l i a  
In Australia there already exists a range of tools to calculate absolute risk of CVD, including the 
Australian Cardiovascular Risk Charts and the Australian Absolute Cardiovascular Disease Risk 
Calculator. There are also many clinical guidelines that relate to the assessment and management of 
CVD risk, including the National Health and Medical Research Council of Australia (NHMRC)-endorsed 
National Vascular Disease Prevention Alliance (NVDPA) Guidelines for the Management of Absolute 
Cardiovascular Disease Risk5 and the Central Australian Rural Practitioners Association (CARPA) 
Standard Treatment Manual.15 In the general Australian population, current clinical uptake is below 
what is considered optimal, with evidence suggesting that around 60% of primary care clinicians 
regularly perform absolute CVD risk assessment16 and there is widespread under-treatment according 
to absolute risk.9 Levels of uptake of the absolute CVD risk approach among Aboriginal and Torres Strait 
Islander populations is unknown. One of the potential barriers to improved clinical uptake is 
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inconsistencies in recommendations in current clinical practice guidelines and, until recently, PBS 
eligibility criteria for statins. 
 
Aim 
The aim of this report was to review current clinical guidelines relevant to Aboriginal and Torres Strait 
Islander absolute CVD risk assessment and management, identify points of alignment and discordance 
between the guidelines and review the evidence-base for the guidelines in relation to these points of 
discordance. Additionally, strategies for keeping clinical guidelines up to date were reviewed. This 
report was commissioned by the Australian Government Department of Health as part of a program of 
work aimed at reducing Aboriginal and Torres Strait Islander CVD morbidity and mortality through 
improving the uptake of an absolute risk approach to CVD assessment and treatment. The review and 
report were undertaken independently by researchers from: the National Centre for Epidemiology and 
Population Health, Research School of Population Health, Australian National University; the Academic 
Unit of General Practice, Medical School, Australian National University; and Rheumatic Heart Disease 
Australia, Menzies School of Health Research. 
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Methods 
G u i d e l i n e  s c o p i n g   
We aimed to identify all Australian clinical practice guidelines that made recommendations on absolute 
CVD risk assessment and management or related to diagnosis/treatment of related chronic conditions 
(hypertension, diabetes, kidney disease, depression). Since all CVD-related guidelines should include 
recommendations for Aboriginal and Torres Strait Islander peoples, we did not restrict our search to 
only those specific to Aboriginal and Torres Strait Islander peoples. In addition, during the scoping 
process, we included guidelines on related conditions regardless of whether they included 
recommendations on CVD risk assessment since it can be argued that they should. Guidelines were 
identified through a combination of database and website searches and stakeholder engagement. Four 
databases were searched: NHMRC Guidelines and Publications Portal, the NHMRC Australian Clinical 
Practice website, the Medical Journal of Australia List of Guidelines and Statements and the Royal 
Australian College of General Practitioners (RACGP) List of Clinical Guidelines.   
 
Search terms: cardiovascular; cardiac; stroke; peripheral vascular disease; Aboriginal; Indigenous; 
Koori; Murray; Goori; prevention; diabetes; kidney; renal; hypertension; blood pressure; dyslipidemia; 
metabolic syndrome; mood; mental; depression; antipsychotics.  
 
Inclusion criteria: Guidelines were included in the review if they met the following criteria: 
1. Included guidance/recommendations on the assessment of primary CVD risk or related to 
treatment/management of common co-morbid conditions (diabetes, kidney disease, 
hypertension, mood disorders); and 
2. Were currently being used in clinical practice in Australia as at September 2017. 
 
Exclusion criteria: Guidelines were excluded if they related solely to secondary CVD prevention (since 
people with prior CVD are automatically considered at high risk and absolute risk scores do not need 
to be calculated), or specifically to clinical management in children or pregnant women. 
 
I d e n t i f i c a t i o n  o f  p o i n t s  o f  d i s c o r d a n c e   
Data extraction: Templates were used to systematically extract data from the relevant guidelines by 
LF, with secondary review by EP. Data extraction focused on three key components: i) a summary of 
general information about the guidelines; ii) assessment of absolute CVD risk scores for Aboriginal and 
Torres Strait Islander peoples, including the recommended approach to calculating risk, age for 
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commencing assessment and frequency of re-assessment; and iii) management of absolute CVD risk 
for Aboriginal and Torres Strait Islander peoples, including risk thresholds and treatment 
recommendations according to risk. Points of concordance and discordance were identified by 
comparing and identifying similarities and differences between the guidelines in the recommendation 
of Aboriginal and Torres Strait Islander CVD risk assessment and management.  
 
E v i d e n c e  r e v i e w  f o r  a l i g n i n g  t h e  g u i d e l i n e s  
For each element of discordance identified, we identified the relevant evidence that informed the 
guidelines. In addition, we undertook a comprehensive search of the literature to identify any further 
relevant evidence published since the development of the latest guideline. This included a systematic 
review of literature related to Aboriginal and Torres Strait Islander or Māori absolute CVD risk 
assessment or management, published since 2012. We included evidence from Indigenous populations 
in New Zealand as such evidence has been used to inform Australian CVD guidelines in the past. We 
also conducted forward and backwards citation searches, used the expert knowledge of the research 
team to identify any missed studies or unpublished evidence, and conducted searches of published 
abstracts of the 2016 and 2017 Cardiac Society of Australia and New Zealand annual scientific meetings 
(abstracts prior to this time were not published in a searchable PDF format).The quality of the included 
studies was assessed using the Quality Assessment Tool for Observational Cohort and Cross-Sectional 
Studies from the National Heart, Lung and Blood Institute. Further details of the search strategy are 
outlined in Appendix A.  
 
R e v i e w  o f  a p p r o a c h e s  f o r  u p d a t i n g  c l i n i c a l  g u i d e l i n e s  
A systematic literature review was conducted to compare strategies for updating clinical guidelines, 
with the aim of identifying the most effective ways of keeping guidelines on absolute CVD risk 
assessment and management up to date. This review was not specific to the Aboriginal health context 
and was not limited to specific disease types. A previous systematic review, published in 2012, that 
examined strategies for monitoring and updating clinical practice guidelines was identified.17 We aimed 
to update this review by systematically searching the literature published from 2012. Details of the 
search strategy are outlined in Appendix B. 
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Findings 
G u i d e l i n e  s c o p i n g  
A total of 228 guidelines1 were identified using four guideline portals and an additional eight guidelines 
were identified using the experience and knowledge of the research team. Of the 236 identified 
guidelines, 14 met the inclusion criteria and were included in this review (see flow chart in Figure 1). 
An overview of the 14 included guidelines is provided in Table 1. Only one guideline, the NVDPA 
Guidelines for the Management of Absolute Cardiovascular Disease Risk, was specifically aimed at 
providing guidance on CVD risk assessment and management, although a further nine guidelines 
included some guidance on absolute CVD risk. Four guidelines related to health more generally or to 
comorbid conditions and did not provide recommendations on CVD risk assessment and management. 
All ten guidelines that provided recommendations on assessing absolute CVD risk also provided specific 
recommendations for assessing Aboriginal and Torres Strait Islander people. However, only one of 
these, the RACGP National Guide to a Preventive Health Assessment for Aboriginal and Torres Strait 
Islander people, was developed specifically and solely for use for Aboriginal and Torres Strait Islander 
populations.  
 
Overall we identified three main guidelines that provided information on absolute CVD risk assessment 
and treatment to clinicians and health practitioners: (1) Guidelines for the Management of Absolute 
Cardiovascular Disease Risk developed by the NVDPA, latest version published in 2012; (2) The CARPA 
Standard Treatment Manual, latest version published in 2014; and (3) the National Guide to a 
Preventive Health Assessment for Aboriginal and Torres Strait Islander people developed by the RACGP 
and the National Aboriginal Community Controlled Health Organisation, latest version published in 
2012. All other guidelines that made recommendations on absolute CVD risk assessment and 
management referred back to the NVDPA guidelines. 
 
                                                             
1 Throughout the text we refer to a guideline as an individual document which provides clinical guidance and 
recommendations 
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Figure 1: Flow diagram of guidelines included in the review 
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Table 1: Summary of included guidelines 
Guideline  
(developer) 
Intended audience Period of evidence review & 
publication date 
Absolute CVD risk 
included? 
Recommendations for 
Aboriginal and Torres 
Strait Islander peoples 
included? 
Aboriginal and 
Torres Strait 
Islander-specific 
guidelines? 
CVD-specific guidelines 
Guidelines for the Management 
of Absolute Cardiovascular 
Disease Risk  
(National Vascular Disease 
Prevention Alliance [NVDPA])5 
General practitioners, 
Aboriginal health workers, 
other primary care health 
professionals and physicians. 
Search dates for evidence: 
2006-June 2010 
 
Published: 2012 
Yes Yes No 
General guidelines 
The Central Australian Rural 
Practitioners Association (CARPA) 
Standard Treatment Manual  
(CARPA Inc., Central Australian 
Aboriginal Congress, Flinders 
University)15 
Practitioners working in 
remote practice in central and 
northern Australia. 
Latest reference: 2011 
 
Published: 2014 (6th Ed.) 
Yes Yes No 
National guide to a preventive 
health assessment for Aboriginal 
and Torres Strait Islander people  
(The Royal Australian College of 
General Practitioners [RACGP])18 
All health professionals 
delivering primary healthcare 
to Aboriginal and/or Torres 
Strait Islander people. 
Latest reference: 2012 
 
Published: 2012 (2nd Ed.) 
Yes Yes Yes 
Therapeutic guidelines 
cardiovascular version 6*  
(Therapeutic Guidelines Limited)19 
Clinicians Latest reference: 2012 
 
Published: 2012 
Yes Yes No 
Guidelines for preventive 
activities in general practice* 
(RACGP)20 
Health professionals Latest reference: 2012 
Published: 2016 (9th Ed.) 
Yes Yes No 
 Review of evidence for the alignment of guidelines on Aboriginal and Torres Strait Islander absolute cardiovascular disease risk  11 
  
 
Guideline  
(developer) 
Intended audience Period of evidence review & 
publication date 
Absolute CVD risk 
included? 
Recommendations for 
Aboriginal and Torres 
Strait Islander peoples 
included? 
Aboriginal and 
Torres Strait 
Islander-specific 
guidelines? 
Chronic Conditions Manual: 
Prevention and Management of 
Chronic Conditions in Australia* 
(Queensland Government, Royal 
Flying Doctor Service Australia, 
and Apunipima Cape York Health 
Council)21 
Clinicians Main absolute CVD 
evidence: 2012 
 
Published: 2015 (1st Ed.) 
Yes Yes No 
Primary Clinical Care Manual  
(Queensland Health, Royal Flying 
Doctor Service (Queensland 
Section))22 
Registered Nurses, Aboriginal 
and Torres Strait Islander 
Health Workers, Midwives, 
and Paramedics who have 
authority to practice under a 
Drug Therapy Protocol in rural 
hospitals, isolated practice 
areas, sexual health, or 
immunisation programs. 
Published: 2016 (9th Ed.) No N/A No 
Putting prevention into practice: 
Guidelines for the 
implementation of prevention in 
the general practice setting  
(RACGP)23 
General practitioners Published: 2006 (2nd Ed.) 
 
Latest reference: 2005 
No, although 
suggests GP could 
use 
‘cardiovascular 
risk calculator’ 
N/A N/A 
Guidelines on related chronic conditions or risk factors 
Guideline for the diagnosis and 
management of hypertension in 
adults – 2016*  
(The National Heart Foundation of 
Australia)24 
Health professionals, 
particularly those working in 
primary care and community 
services. 
Search dates for evidence: 
2010-2014, with key 
literature identified up to 
December 2015 
 
Published: 2016 
Yes Yes No 
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Guideline  
(developer) 
Intended audience Period of evidence review & 
publication date 
Absolute CVD risk 
included? 
Recommendations for 
Aboriginal and Torres 
Strait Islander peoples 
included? 
Aboriginal and 
Torres Strait 
Islander-specific 
guidelines? 
General practice management of 
type 2 diabetes* 
(RACGP and Diabetes Australia)25 
Health professionals Latest reference: 2016 
 
Published: 2016 
Yes Yes No 
Chronic Kidney Disease 
Management in General Practice*  
(The Australian Kidney 
Foundation)26 
General practitioners Latest reference: 2014 
 
Published: 2015 (3rd Ed.) 
Yes Yes No 
Chronic Kidney Disease Guidelines  
(Kidney Health Australia – Caring 
for Australians with Renal 
Impairment (KHA-CARI))27 
Clinicians and health care 
workers 
Published: 2013 
 
Latest reference: 2012 
No N/A N/A 
Smoking, nutrition, alcohol, 
physical activity (SNAP): A 
population health guide to 
behavioural risk factors in general 
practice* 
(RACGP)28 
General practitioners and 
practice staff 
Published: 2015 (2nd Ed.) Yes Yes No 
Australian guidelines for the 
treatment of adults with acute 
stress disorder and posttraumatic 
stress disorder  
(Australian Centre for 
Posttraumatic Mental Health)29 
Health practitioners, 
consumers, and policy makers 
Published: 2013 
 
Latest reference: 2012 
No N/A N/A 
*Based on NVDPA 2012 guidelines
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P o i n t s  o f  a l i g n m e n t  b e t w e e n  g u i d e l i n e s  
An overview of recommendations for the assessment and management of CVD absolute risk in the 
relevant Australian clinical guidelines is provided in Tables C1 and C2 in Appendix C. We identified four 
commonalities across the guidelines: definitions of clinically-determined high risk groups, 
recommended risk score, risk thresholds for treatment, and treatment targets for lipids and lifestyle 
modification. 
 
Clinically-determined high risk 
In addition to recommending assessment of absolute CVD risk, most guidelines consistently 
recommend treatment of people with extremely elevated levels of single risk factors or those with 
clinical conditions that increase susceptibility to CVD. The reviewed guidelines consistently consider 
people with the following conditions to be at high risk of absolute CVD without the need to calculate 
an absolute risk score: diabetes and albuminuria; diabetes and being over the age of 60; chronic kidney 
disease; systolic blood pressure ≥180 mmHg; and/or total cholesterol ≥7.5 mmol/L. In addition, the 
NVDPA (and all other guidelines that refer back to these) and the RACGP guidelines consider people to 
be at high risk if they have a diastolic blood pressure of ≥110 mmHg or a previous diagnosis of 
hypercholesterolaemia. In all guidelines, people that have had a prior CVD event or Aboriginal and 
Torres Strait Islander people who are aged >74 years (additionally, in the CARPA guidelines, non-
Indigenous people aged 75 years or older) are assumed to have a high risk of CVD and an absolute CVD 
risk score does not need to be calculated. People with prior CVD are treated according to different sets 
of guidelines that focus on the management of stroke, heart failure and acute coronary syndrome.30-32 
 
Recommended risk score 
The guidelines consistently recommend using Australian-specific risk charts or calculators based on the 
FRE. Almost all guidelines suggest using the online Australian Absolute Cardiovascular Disease Risk 
Calculator (www.cvdcheck.org.au), developed by the NVDPA, with the exception of the CARPA 
Standard Treatment Manual which publishes its own charts that have been adapted from those created 
by the NVDPA and the New Zealand Cardiovascular Risk Charts (2009). The General Practice 
Management of Type 2 Diabetes guideline also provides information about additional resources 
including the New Zealand Cardiovascular Risk Charts (2009) and the Heart Foundation New Zealand 
Know Your Numbers website (www.knowyournumbers.co.nz). 
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Risk thresholds for treatment 
Except for the Chronic Kidney Disease Management in General Practice guideline and the SNAP 
guideline where risk thresholds for treatment are not explicitly discussed, all guidelines consistently 
state that treatment should commence when there is more than a 15% risk of a primary CVD event 
over the next five years. These treatments generally include advice and support for lifestyle changes 
(e.g. in relation to diet, physical activity and smoking cessation) and commencement of blood-pressure- 
and lipid-lowering therapy. Although none of the guidelines recommends the immediate routine use 
of medications in those at moderate risk (10-15% risk of a primary CVD event in the next five years), 
the NVDPA and the RACGP guidelines recommend lifestyle changes and consideration of blood 
pressure and lipid-lowering therapy for people where treatment targets are not met after 3-6 months 
of lifestyle changes or for people who have additional risk factors. Additional risk factors include 
persistently elevated blood pressure (>160/100 mmHg), a family history of premature CVD, and 
populations such as Aboriginal and Torres Strait Islander peoples where the FRE is likely to 
underestimate risk (see below). 
 
Lifestyle and lipid treatment targets 
All three main guidelines recommend aiming for health behaviour changes comprising smoking 
cessation, dietary changes including reducing salt intake (specified target of <4g/day in the RACGP 
guidelines) and reducing alcohol consumption (specified as a maximum two standard drinks/day in the 
CARPA and RACGP guidelines). The CARPA and NVDPA, but not the RACGP, guidelines also recommend 
increasing physical activity (specified target of at least 30 minutes of moderate intensity physical 
activity on most or all days of the week in the NVDPA guidelines). While the CARPA guidelines 
recommend monitoring lipids and treating to target, only the NVDPA guideline (and other guidelines 
that refer back to the NVDPA guidelines) provide specific lipid targets of: <4 mmol/L for total 
cholesterol, ≥1 mmol/L for high-density lipoprotein, <2 mmol/L for low-density lipoprotein and 
triglycerides, and <2.5 mmol/L for non-high-density lipoprotein.  
 
P o i n t s  o f  d i s c o r d a n c e  b e t w e e n  t h e  g u i d e l i n e s  
Four key points of discordance were identified between the guidelines:  
 age at which screening for CVD risk is recommended to commence for Aboriginal and Torres 
Strait Islander people; 
 whether CVD risk should be automatically adjusted upwards for Aboriginal and Torres Strait 
Islander people;  
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 how frequently CVD risk should be re-assessed; and  
 the recommended treatment targets for blood pressure. 
 
Age for commencing screening 
All guidelines, except the CARPA Standard Treatment Manual, suggest screening should begin at 35 
years for Aboriginal and Torres Strait Islander people and 45 years for non-Indigenous people. The 
CARPA Standard Treatment Manual recommends starting screening at 20 years of age for Aboriginal 
and Torres Strait Islander peoples and 45 years of age for non-Indigenous people. 
 
Risk adjustments 
Although all the guidelines recognise that Aboriginal and Torres Strait Islander peoples are at increased 
risk of CVD, and that the FRE is likely to underestimate risk in this population, only the CARPA Standard 
Treatment Manual and the National Heart Foundation hypertension guidelines make a specific 
recommendation to revise absolute risk prediction for Aboriginal and Torres Strait Islander people 
upwards by 5%. An additional 5% is also automatically added to absolute CVD risk scores for Aboriginal 
and Torres Strait Islander people in the CARPA risk calculator that is integrated into the Communicare 
patient information and recall system and the Northern Territory’s Primary Care Information System 
(PCIS).2  
 
Frequency of risk re-assessment 
Recommendations on how often people should have their absolute CVD risk re-assessed vary between 
guidelines. The RACGP Aboriginal and Torres Strait Islander-specific guidelines recommend re-
assessment of all Aboriginal and Torres Strait Islander people aged 35-74 annually, while the RACGP 
Guidelines for Preventive Activities in General Practice recommend re-assessment every 2 years. The 
CARPA Standard Treatment Manual, the NVDPA guidelines, the Therapeutic Guidelines Cardiovascular 
version 6, and the General Practice Management of Type 2 Diabetes guidelines recommend re-
assessment based on absolute CVD risk status every 2 years for those at low risk (<10%), every 6-12 
months for those at moderate risk (10-15%) and according to clinical context for those at high risk 
(>15%).  
                                                             
2 The other two major primary care software programs, Medical Director and Best Practice, have the FRE 
integrated but do not add an additional 5% to calculated CVD risk for Aboriginal and Torres Strait Islander 
people.  
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Blood pressure treatment targets 
The CARPA, NVDPA and the National Heart Foundation of Australia hypertension guidelines generally 
agree that lower blood pressure—up to reasonable clinical limits—is better for CVD risk but differ in 
terms of recommended treatment targets that are recommended. The RACGP guidelines do not 
explicitly state any blood pressure treatment targets. The CARPA Standard Treatment Manual suggests 
aiming for blood pressure <130/80 mmHg but explicitly states that medications should not be stopped 
once targets are reached. The NVDPA guidelines have a slightly higher treatment target of ≤140/90 
mmHg except for those with diabetes and albuminuria where a blood pressure target of ≤130/80 
mmHg is suggested. It is acknowledged that while treatment targets can be used to monitor treatment 
effects, more intensive blood pressure lowering is associated with greater reductions in CVD events 
and this should be assessed against the benefits and harms of treatment in individual patients. The 
National Heart Foundation of Australia hypertension guideline recommends aiming for systolic blood 
pressure <140 mmHg in people with uncomplicated hypertension and considering a lower target of 
<120 mmHg in people with high CVD risk (10-year risk of >20%) with increased monitoring to identify 
any adverse side-effects. 
 
E v i d e n c e  r e v i e w  f o r  a l i g n i n g  t h e  g u i d e l i n e s  
After reviewing the evidence cited in the current clinical guidelines, one study reported original 
research examining how well the FRE predicts Aboriginal and Torres Strait Islander CVD risk. No 
evidence was cited in relation to three of the four main points of discordance between the guidelines: 
age of commencing screening, risk adjustment, and frequency of risk re-assessment. Multiple sources 
of primary data were cited in the guidelines in relation to blood pressure targets. We then conducted 
a systematic literature search of MEDLINE and Scopus for any relevant evidence published since release 
of the guidelines, identifying 263 papers. Of these, three met our inclusion criteria (see flow chart of 
study selection in Appendix D). No further relevant studies were located from the forwards and 
backwards citation searches of references from the included studies or through a search of abstracts 
of the Cardiac Society of Australia and New Zealand annual scientific meetings. An additional study was 
found through stakeholder engagement. A summary of the characteristics of the relevant studies is 
included in Table 2.  
 
Of the five identified relevant studies, two involved Aboriginal peoples from the Northern Territory, 
one included Aboriginal peoples from Western Australia, one included Aboriginal and Torres Strait 
Islander peoples from Far North Queensland and one involved Indigenous New Zealand populations. 
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All studies were found to be of fair or good quality. Approximately equal numbers of men and women 
were included in each of the studies. Two studies assessed coronary heart disease rates per 1,000 
person years,33, 34 one assessed ten-year absolute CVD risk35 and two assessed both five- and ten-year 
absolute CVD risk.36, 37 
 
Two studies assessed how well the FRE performed for Aboriginal peoples from remote Northern 
Territory34 and urban Western Australia (Table 3).33 Both studies found that the FRE underestimated 
Aboriginal CVD risk; observed rates of coronary heart disease were estimated at 11-13 cases per 1,000 
person years and were approximately 2.5 times higher than the predicted rates. The FRE particularly 
underestimated CVD risk in younger women (under the age of 35) in remote communities where the 
observed rates were 30 times higher than those predicted.34 
 
Since there is evidence that the FRE underestimates risk in Aboriginal people, the CARPA Standard 
Treatment Manual and associated electronic decision support tools and the National Heart Foundation 
of Australia hypertension guideline adjust risk automatically upwards by 5% for Aboriginal and Torres 
Strait Islander people. This is based on similar recommendations for the Indigenous population and 
other at-risk populations (those with a family history of premature CVD and those with diabetes who 
also have microalbuminuria or who have had diabetes for 10 or more years or who have HbA1c 
consistently 8%) in the New Zealand Cardiovascular Guidelines Handbook.4 Calibration (how well 
predicted rates match the observed rates) of this New Zealand adjusted score was compared to that 
for the unadjusted FRE in a sample of 21,000 Māori, Pacific and Indian people (Table 3).37 In these 
populations that are exposed to high levels of risk factors, the FRE underestimated five-year CVD risk 
by 1.1-2.2% in people with low risk and overestimated risk by 2.4-4.1% in people with high predicted 
risk. The New Zealand adjusted score overestimated risk in the Māori, Pacific and Indian participants 
by around 1-5% in people at low risk and 7-9% in people with predicted high risk. This suggests that the 
automatic upward adjustment of the FRE by 5% may over-correct the underestimation in some high 
risk populations and the authors suggest that population-specific risk scores are needed.37  
 
Work on developing population-specific risk scores for Aboriginal and Torres Strait Islander peoples is 
starting in Australia. Two related studies by Adegbija and colleagues (both published in 2015, listed as 
a single entry in Tables 2 and 3) aimed to predict absolute CVD risk using a simplified risk score 
consisting of age and waist circumference. Age and waist circumference were associated with absolute 
CVD risk but common performance measures, including calibration and discrimination (how well the 
score discriminates between people with and without CVD), were not reported. They found that the 
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established waist circumference cut-offs of 88cm for women and 102cm for men overestimated and 
underestimated CVD risk, respectively.35 Among the Aboriginal population they estimated a waist 
circumference of 91.5cm for men and 92.5cm for women was associated with a similar absolute CVD 
risk as having a body mass index in the overweight range.38 Hua and colleagues (2017) used Aboriginal 
and Torres Strait Islander data from 1,448 people in 26 communities in Far North Queensland to 
recalibrate the FRE. The recalibrated score had improved the ability to discriminate between those with 
and without CVD and was better calibrated than the FRE alone.36 However, their approach did not take 
into account people at clinically-determined high risk, even though the vast majority of Aboriginal and 
Torres Strait Islander peoples classified as being at high absolute risk are so categorised because of 
clinical factors, especially diabetes and chronic kidney disease.8 At this stage the recalibrated score has 
also not been validated in a different Australian Aboriginal and Torres Strait Islander population, which 
is essential before a recalibrated risk score can be recommended for use in practice.  
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Table 2: Characteristics of included studies examining absolute cardiovascular disease risk assessment in Aboriginal and Torres Strait Islander people or 
Indigenous New Zealand populations 
Author 
 
Objective Study design Study setting and  
target pop 
Sample size Sex (%) Age range  CVD definition 
Studies cited in current clinical guidelines (published prior to 2010) 
Wang et al., 
200534 
Assess whether the FRE 
predicts risk in 
Aboriginal people 
Prospective 
cohort study 
Aboriginal people in 
remote Northern 
Territory region 
687 Men (52) and 
women (48) 
20-74 years Predicted coronary heart 
disease (CHD) (myocardial 
infarction, death from CHD, 
angina pectoris and 
coronary insufficiency) 
rates per 1000 person 
years 
Relevant studies identified through expert collaboration  
Bradshaw et al., 
200933 
Assess whether the FRE 
predicts risk in urban 
Aboriginal people 
Cohort study Aboriginal people in 
Perth, Western 
Australia 
891 Men (45) and 
women (55) 
18-80 Predicted CHD event 
(ischaemic heart disease, 
coronary revascularisation, 
cardiac-related death) 
rates per 1000 person 
years 
Studies identified through a systematic literature search (2010-2017) 
Adegbija et al., 
201535, 38 
Prediction of 
cardiovascular disease 
risk using 
waist circumference in 
Aboriginal and Torres 
Strait Islander people 
Prospective 
cohort study 
Aboriginal people in a 
remote community in 
the Northern Territory 
920  Men (51) and 
women (49) 
18-76 years  10-year absolute CVD risk 
Hua et al., 201736 Validation of the 1991, 
2008 and recalibrated 
FRE CVD models 
Cohort study 26 remote Aboriginal 
and Torres Strait 
Islander communities 
in Far North 
Queensland who 
undertook Well 
Person’s Health Check 
cohort 
1448 Men (48) and 
women (52) 
30-74 years 5- and 10-year CVD risk. 
CVD defined as CHD 
(including myocardial 
infarction, angina 
pectoris and coronary 
insufficiency), CHD death, 
stroke, congestive heart 
failure and peripheral 
vascular disease 
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Author 
 
Objective Study design Study setting and  
target pop 
Sample size Sex (%) Age range  CVD definition 
Riddell et al., 
201037  
Assess the calibration 
of the FRE and New 
Zealand adjusted FRE 
Prospective 
cohort study 
European and Māori, 
Pacific and Indian 
participants in New 
Zealand 
21,026 
Māori, 
Pacific, and 
Indian 
Not specified but 
there were 55% 
men and 45% 
women in the 
overall population 
(including non-
Indigenous 
people). 
30-74 years 5-year CVD risk. CVD 
defined as ischaemic heart 
disease, stroke or transient 
ischaemic attack, 
peripheral vascular disease, 
percutaneous coronary 
intervention and/or 
coronary artery bypass 
graft 
 
Table 3: Details of CVD absolute risk assessment and findings of included studies relating in Aboriginal and Torres Strait Islander people or Indigenous New 
Zealand populations 
Study Age of screening 
commencement 
 
Factors defining clinically 
determined high risk 
Risk score and 
adjustments 
Findings Quality rating  
(good, fair poor) 
 
Studies cited in current clinical guidelines (published prior to 2010) 
Wang et al., 2005 20 Not specified FRE Observed CHD rates were 2.5 times the FRE predicted rates 
(11 CVD cases per 1000 person-years vs. predicted 4.4 per 
1000 person-years). Underestimation was particularly high in 
women, especially younger women, with the observed rates 
of CVD (3.3 cases per 1000 person-years) being around 30 
times higher in Aboriginal women under the age of 35 than 
those predicted by the FRE (predicted 0.1 per 1000 person-
years).  
Fair 
Relevant studies identified through expert collaboration (published prior to 2010) 
Bradshaw et al., 
2009 
18 Recorded diagnosis of 
CHD, reported diabetes, 
hypertension and 
obesity 
FRE Observed CHD rates were comparable to those seen in Wang 
et al. (2005), 12.6 CHD cases per 1000 person-years. 
Comparable trends were seen in all age categories (though 
higher rates seen in middle age categories [35-44 and 45-54] 
in the urban populations). 
Fair 
Studies identified through a systematic literature search (2010-2017) 
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Study Age of screening 
commencement 
 
Factors defining clinically 
determined high risk 
Risk score and 
adjustments 
Findings Quality rating  
(good, fair poor) 
 
Adegbija et al., 
2015 
18 Not specified Waist 
circumference and 
age were the only 
two predictors used 
 
Absolute CVD risk increased with increasing age and waist 
circumference. The established waist circumference cut-offs 
of 88cm in women and 102cm in men overestimated CVD risk 
in women and underestimate it in men suggesting different 
cut-points are needed for Aboriginal populations. Another 
paper by this group suggests waist circumference cut-offs of 
91.5cm in men and 92.5cm for women have similar absolute 
CVD risks as having a body mass index in the overweight 
range. 
Good 
Hua et al, 2017 35 Not specified  FRE 1991 & 2008.  FRE significantly underestimated the CVD risk by 1/3. The 
1991 model showed good discrimination ability but poor 
calibration. After recalibration the 2008 model corrected the 
underestimation and improved calibration for 5-yr risk 
prediction. A 5-year absolute CVD risk chart for the Aboriginal 
and Torres Strait Islander people was generated, based on a 
recalibration of the 2008 FRE. The recalibrated risk score 
showed a slightly improved risk discrimination compared to 
the uncalibrated FRE and improved calibration. External 
validation has not yet been done. 
Fair 
Riddell et al., 
2010 
30 Not specified. People 
with diabetes plus 
nephropathy or a 
diagnosed genetic lipid 
disorder were excluded. 
FRE and a New 
Zealand adjusted 
FRE which includes 
adding 5% to the 
predicted risk for 
people of Māori, 
Pacific or Indian 
subcontinent 
ethnicity or with 
other risk factors 
The FRE underestimated CVD risk by 1.1-2.2% in people with 
low risk and overestimated risk by 2.4-4.1% in people with 
high predicted risk. The NZ adjusted FRE overestimated risk in 
the  Māori, Pacific and Indian participants by around 1–5% in 
people at low risk and 7–9% in people with predicted high 
risk. 
Fair 
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R e v i e w  o f  a p p r o a c h e s  f o r  u p d a t i n g  c l i n i c a l  g u i d e l i n e s  
Current approach for updating CVD clinical guidelines in Australia 
The NVDPA guidelines, last published in 2012, use a comprehensive but resource-intensive approach 
to guideline development and updating which involves a combination of literature searches and 
reviewing of the evidence, formulation of recommendations, and public consultation.5 To formulate 
the recommendations, an expert consensus-based approach is used whereby several members of the 
expert working group use the information from the literature review to draft recommendations. These 
are sent to the whole expert working group for feedback until a consensus agreement of >75% is 
achieved (this required two circulation rounds for the last update of the NVDPA guideline in 2012). This 
process can take several years to complete which means that some aspects of the guidelines are likely 
to be out of date by the time they are published. Furthermore, the resources required mean that 
updating is conducted infrequently. In an effort to ensure more up to date clinical guidelines, other 
approaches such as the creation of ‘living’ guidelines are being explored. For example, the Cancer 
Council of Australia is replacing printed versions of guidelines with an online wiki platform where 
continuously updated guidelines are published (http://wiki.cancer.org.au/australia/Guidelines). The 
sections below provide an overview of the current evidence for approaches to evaluating if clinical 
guidelines are out of date, different literature search strategies for updating guidelines, and approaches 
for ensuring guidelines are kept up to date. Evidence has been drawn from previous systematic reviews 
of this topic,17, 39, 40 supplemented by an updated search of the literature from 2012 onwards. We 
identified a total of 10 relevant studies in addition to those captured in the previous systematic reviews 
(see flow chart of study selection in Appendix E), with summaries of the evidence provided in Tables 
F1-F2 in Appendix F. 
 
Approaches to evaluating if guidelines are out of date 
Different tools have been developed to assist with deciding whether guidelines need updating. 
Examples include flow-charts to help guide the development group through the process of determining 
the type and scope of an update (Appendix G)39 and questionnaires as part of a two-stage document 
assessment and review approach.41 In the first stage of this document assessment and review approach 
a clinical expert and methodologist assess the guidelines using a six-item questionnaire which classifies 
guidelines into endorse, defer, review or archive (Appendix H).41 A four-item questionnaire is then used 
for guidelines that are to be reviewed to help determine the impact of any new evidence and any 
actions to be taken (Appendix I). However, this document assessment and review approach is time 
consuming (median time of 167 days) so although it may help guide decisions about when to update 
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guidelines, it is unlikely that this would shorten or make less onerous the process of updating 
guidelines.  
Literature search strategies for updating guidelines 
There are two main approaches that are used for finding relevant literature to update clinical 
guidelines. Restrictive searches use specific search terms to focus the updated literature review to 
certain topics, while exhaustive searches aim to canvass all the relevant literature. An exhaustive search 
is the gold standard strategy for updating guidelines,17 but this approach is generally more 
burdensome, costly and time consuming compared to restrictive searches.17, 42 Restrictive searches are 
potentially more effective than exhaustive searches and take significantly less time to perform, but may 
fail to identify studies that could potentially trigger an update.43-45 A possible area for future research 
would be to assess the use of a combined approach whereby a restrictive search strategy in addition 
to input from experts is used to identify key references for recommendations that are already based 
on good evidence, and an exhaustive search strategy in addition to input from experts is used to identify 
evidence for recommendations based on little or weak evidence. A scoring algorithm has also been 
developed to select the most relevant evidence for guidelines.46 Relevant articles are retrieved using a 
literature search and then filtered using a set of criteria. An algebraic model is then used to score the 
evidence based on its relevance. Validation of this process using 40 random guidelines indicated that 
90% of relevant articles were found.46  
 
Strategies for keeping guidelines up to date 
Generally the process for updating guidelines is poorly described in guideline handbooks.47 In many 
circumstances, partially updating guidelines can be more appropriate than updating the whole clinical 
guideline.39 Full updates are resource intensive, with the costs and effort comparable to those required 
for the initial development.39 Partial (or ‘selective’) updates can provide updates in a timeframe that 
suits the fast-paced developments in health care. However, deciding which parts or recommendations 
in the guideline need updating can be difficult and subjective.39, 45 Input from stakeholders and experts 
can reduce subjectivity47 but this may slow down the updating process if feedback is not timely or if a 
consensus is not reached.41, 43 A common approach to updating guidelines is to re-evaluate guidelines 
within a specified timeframe. For Australian CVD-related guidelines this is typically occurs every five 
years in practice, but most handbooks and studies suggest re-evaluating guidelines more frequently at 
around every two to three years.40, 45  
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A novel approach that has emerged is the idea of ‘living’ guidelines that are regularly or continuously 
updated. Living guidelines are developed using similar methodology as is used for partial updates but 
updates are made on a continuous rolling basis. The Scottish Intercollegiate Guidelines Network (SIGN) 
manual for guideline development (SIGN 50) suggests that living guidelines are updated annually or 
biannually but with timing that depends on how fast new evidence emerges.48 The specific parts of the 
guidelines to be updated will depend on what new evidence has been identified. For example, this 
methodology is used to keep the British Guideline on the Management of Asthma up to date, with draft 
updates presented at the British Thoracic Society biannual meetings and draft updates published on 
both the SIGN and British Thoracic Society websites for comment for a fixed period of time. A similar 
approach could be used to keep the main NVDPA guidelines up to date, with draft updates presented 
to an advisory committee of health care experts and with the most up to date guidelines published on 
relevant websites (such as the Heart Foundation webpage) or a custom-built wiki platform.  
 
Tools to support the development and dissemination of updated and living guidelines are becoming 
available. For example, an online software application, called MAGICapp (Making GRADE the Irresistible 
Choice, available at: http://magicproject.org/) can support the creation of electronic guidelines and 
publication on the web and on smartphones and tablets and the creation of decision aids and 
integration with electronic medical records. When guidelines are modified or updated these end-user 
outputs will be automatically updated to reflect the guideline changes.49 The use of electronic tools 
and publication platforms, such as the Cancer Council of Australia wiki platform, may facilitate guideline 
updates while maintaining methodological rigor and transparency.47 The MAGICapp is currently used 
to support development of several international and national guidelines including the NHMRC 
Guidelines for the Prevention and Control of Infection in Healthcare. 
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Discussion 
S u m m a r y  o f  k e y  f i n d i n g s  
We identified three main guidelines that guide Aboriginal and Torres Strait Islander absolute CVD risk 
assessment and management in Australia: the NVDPA Guidelines for the Management of Absolute 
Cardiovascular Disease Risk; the CARPA Standard Treatment Manual; and the RACGP National Guide to 
a Preventive Health Assessment for Aboriginal and Torres Strait Islander People. All other guidelines 
that make recommendations on absolute CVD risk primarily relate back to the guidance of the NVDPA 
guideline. Focusing on alignment of the three main clinical guidelines is therefore likely to ensure 
consistency among the guidelines going forward. This review of the evidence is timely as the NVDPA 
guidelines were due to be updated in 2017 and the RACGP guidelines were in the process of being 
updated at the time of writing this report.  
 
Reassuringly, in areas where there is strong empirical evidence (such as clinically determined high risk, 
risk scores and lipid treatment targets), recommendations were generally consistent across the clinical 
guidelines. The guidelines diverged with respect to recommendations that were mostly based on 
consensus-based expert opinion. The four main points of discordance identified included the age at 
which to commence absolute CVD risk assessment, additional risk adjustments for people identifying 
as Aboriginal or Torres Strait Islander, how often CVD risk should be assessed, and exact treatment 
targets for blood pressure. At the time of development of most of these guidelines there was little 
empirical evidence to inform the first three of these points. In the section below (‘Evidence for aligning 
the guidelines’) we outline the current evidence for each of main points of discordance between the 
guidelines. 
 
In addition to aligning the guidelines so that consistent clinical messages are provided, it is important 
to consider the most appropriate ways of keeping the guidelines up to date in the future. This is 
particularly important as more empirical evidence to guide Aboriginal and Torres Strait Islander CVD 
risk assessment and management becomes available (see ‘Future directions’ below). Up to half of all 
clinical guidelines become out of date within six years,50 and given how long the updating process can 
take, recommendations in some guidelines may be out of date by the time of publishing. A promising 
strategy is the idea of living guidelines which involve continuously updating sections of guidelines as 
new evidence becomes available. Similar to new measures by the Cancer Council of Australia, the most 
up to date version of CVD absolute risk assessment and management guidelines, as well as draft 
updates for comment, could be published and accessed via an online wiki platform rather than 
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published as hard-copies. Such an approach can be less resource intensive and ensure guidelines are 
updated and disseminated to users as new evidence becomes available. However, consideration needs 
to be given as to how this would be done in practice and who would be responsible for decision-making, 
as well as when guideline recommendations should be integrated into clinical decision support 
software, as is done for the CARPA guidelines. Tools such as MAGICapp may be useful to support 
reflecting guideline updates in clinical software.  
 
E v i d e n c e  f o r  a l i g n i n g  t h e  g u i d e l i n e s  
Age for commencing screening 
All the guidelines, except for the CARPA Standard Treatment Manual, recommend Aboriginal and 
Torres Strait Islander CVD risk assessment should commence at age 35. The CARPA Standard Treatment 
Manual recommends an earlier starting age of 20 years. Although the current version of the RACGP 
guideline also recommends commencing screening, using clinically-determined high risk categories and 
the FRE, from the age of 35 years, the newest version of this guideline (currently being updated) will 
recommend commencing screening from the age of 30 years instead. Although not specifically a 
guideline, the Essential Service Standards for Equitable National Cardiovascular Care (ESSENCE) 
recommends that Aboriginal and Torres Strait Islander people aged 15 years and over should be offered 
a cardiovascular risk assessment using a validated absolute risk algorithm at least once every year.51  
 
At the population-level, Aboriginal and Torres Strait Islander CVD risk occurs earlier in life compared to 
non-Indigenous Australians. Nationally representative data from the 2012-13 Australian Aboriginal and 
Torres Strait Islander Health Survey found that 9% of Aboriginal and Torres Strait Islander people aged 
18-34 had self-reported CVD, double that reported by non-Indigenous Australians, and 52% of 
Aboriginal and Torres Strait Islander CVD hospitalisations occur among those aged <55 years compared 
to 17% for non-Indigenous Australians.1 Using data from the 2012-13 National Aboriginal and Torres 
Strait Islander Health Measures Survey, an estimated 1.1% of 18-24 year olds and 4.7% of 25-34 year 
old Aboriginal and Torres Strait Islander people were at high absolute primary risk of CVD.8 It should be 
noted that 4.0% of the general population aged 45-54 is at high primary CVD risk.8 This evidence 
suggests high CVD risk occurs earlier in life for Aboriginal and Torres Strait Islander people than is 
targeted in most of the current guidelines, and Aboriginal and Torres Strait Islander people between 
the ages of 18 and 34 experience an equivalent level of risk to the general population aged 45-54 years. 
However, it is not clear at what age risk assessment should commence within this interval of 18-34 
years. The FRE is only validated for use in people aged 30-74,52 and since age is the main driver of 
 Review of evidence for the alignment of guidelines on Aboriginal and Torres Strait Islander absolute cardiovascular disease risk  27 
  
 
predicted CVD risk using the FRE, short-term five- and ten-year absolute risk scores tend to 
underestimate risk in younger people who do not have clinically-determined high risk, even if they have 
several other CVD risk factors. Although there is some evidence that the FRE underestimates CVD risk 
in Aboriginal and Torres Strait Islander people, there is no direct evidence about whether, and to what 
extent, the NVDPA algorithm which includes both clinically-determined high risk categories and 
absolute risk estimated from the FRE underestimates risk in this population. Based on unpublished data 
from the 2012-13 National Aboriginal and Torres Strait Islander Health Measures Survey, over 75% of 
those who were at high CVD risk were identified based on clinically-determined high risk categories, 
using the NVDPA algorithm; the proportion was even higher at younger ages.8 Hence, identification 
and management of those with diabetes and chronic kidney disease is an important component of 
improving CVD health.  
 
Risk adjustments 
Risk scores are better at predicting risk when the population they are applied to is similar to the 
population used to derive the risk score or if the risk score has been recalibrated for use in the relevant 
population. Currently, no Aboriginal and Torres Strait Islander risk scores have been developed and 
validated, although research is progressing in this area. Available validated risk scores, such as the FRE, 
tend to underestimate risk in Indigenous populations, including Aboriginal and Torres Strait Islander 
peoples and Māori people in New Zealand.33, 34, 37 The FRE was developed using data from a cohort of 
people from Framingham, Massachusetts in the US, originally set-up in the 1940s,53 whose profile of 
risk factors and CVD events rates differ greatly from those observed in Aboriginal and Torres Strait 
Islander communities.  
 
The New Zealand Cardiovascular Guidelines Handbook currently recommends adding 5% to the 
calculated risk for Māori and Pacific peoples and people from the Indian subcontinent.4 Based on the 
New Zealand recommendations, a similar risk adjustment is used in the CARPA Standard Treatment 
Manual and is available in risk calculators within Communicare and PCIS software where the CARPA 
guideline recommendations are followed. The decision to adjust risk scores by adding 5% to scores for 
New Zealand Indigenous and other at-risk populations was based on expert opinion by the NZGG (New 
Zealand Guidelines Group) Guidelines development team, building on evidence that these people are 
exposed to greater levels of CVD risk factors and are at higher risk of CVD events. More recent work 
from New Zealand suggests that this 5% risk adjustment can lead to overestimating CVD risk in Māori, 
Pacific, and people of Indian origin in New Zealand.37 While this might be preferable to underestimating 
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risk, no studies have been conducted to assess the validity of adjusting CVD risk scores upwards by 5% 
in Aboriginal and Torres Strait Islander people. There is a clear need for risk scores to be developed or 
recalibrated specifically for Indigenous populations. Work in this area has commenced in Australia with 
attempts at recalibrating the FRE for Aboriginal and Torres Strait Islander peoples.36 However, the 
impacts of this study are limited as clinically-determined high risk was not taken into account, the 
recalibrated equation has not been externally validated, and it is not clear whether a single recalibrated 
score can be applied across different Aboriginal and Torres Strait Islander populations across Australia. 
Further inroads are likely in the future (see more information in ‘Future directions’ below). 
 
Frequency of risk re-assessment 
There was variation between the guidelines in recommendations for how often CVD risk should be re-
assessed. Recommendations varied from set intervals (such as every two years) to risk-specific 
intervals, and none of the guidelines provided suggestions specific for Aboriginal and Torres Strait 
Islander people. These differences are not confined to Australian guidelines, with variations seen across 
international CVD risk assessment and management guidelines.3, 31, 54 This is likely due to the paucity of 
evidence on optimal intervals for risk assessment, with recommendations being developed using 
consensus-based expert opinion rather than published literature. Australian non-Indigenous evidence 
shows there is large variation in how often general practitioners think CVD risk should be re-assessed.55 
After reviewing hypothetical patient case files, re-assessment within six months was recommended for 
most (71%) patients, which is a much shorter time-frame than that recommended by most guidelines. 
This study suggests that among the general Australian population general practitioners were not aware 
of or did not follow recommended time intervals for risk re-assessment. However, the study provides 
no evidence on how often risk should be re-measured.  
 
We were only able to find one study that quantitatively assessed how often CVD risk should be re-
assessed.56 Published in 2013, after development of most of the current guidelines, the study used data 
from longitudinal cohort studies in Japan and the US to assess the probability that participants with 
low-moderate risk would cross the treatment threshold (in this case >20% risk of CVD over a ten-year 
time frame) at specific times. The results suggest that people with a baseline risk of <10% over 10 years 
do not need to be re-assessed for a further 8-10 years, those with a 10-<15% risk may need risk re-
assessment somewhere between 3-8 years, and those with a 15-<20% may need to be re-assessed 
within one year. The results of this study suggest that recommendations for risk re-assessment should 
be based on initial level of risk (as is outlined in the NVDPA and CARPA guidelines) but further research 
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is needed to specify the optimal re-assessment intervals for Australian (Aboriginal and Torres Strait 
Islander and non-Indigenous) risk thresholds.  
 
Blood pressure treatment targets 
The guidelines generally provided a consistent message that lower blood pressure—within reasonable 
clinical limits—was better for improved CVD outcomes, but there were differences in the exact blood 
pressure targets recommended, likely due to the difference in timing of previous guideline updates. 
This point of discordance was not specific to Aboriginal and Torres Strait Islander people, and was 
instead a general point of difference between the guidelines. In contrast to the other three points of 
discordance, there is strong empirical evidence to inform recommendations on blood pressure targets. 
Earlier evidence from clinical trials found no difference in CVD events between people with type 2 
diabetes treated to a target of <120 mmHg and <140 mmHg.57 This earlier evidence informed guidelines 
published in 2012 or prior, such as the NVDPA guidelines which recommend a systolic blood pressure 
target of <140 mmHg. More recent evidence suggests that greater reductions in CVD events can be 
achieved with lower blood pressure targets. The Systolic Blood Pressure Intervention Trial (SPRINT) 
allocated 9,361 people at high risk of CVD (ten year risk of ≥20%) to treatment targets of <120 mmHg 
or <140 mmHg.58 Those treated to the lower systolic blood pressure target of <120 mmHg had fewer 
CVD events and lower risk of all-cause mortality over a 3-year period, although they also experienced 
a greater number of adverse events. A systematic review and meta-analysis published in 2016, included 
over 600,000 participants contributing data to SPRINT and to 122 other clinical trials, found a 20% 
reduction in the risk of CVD events and a 13% reduction in all-cause mortality for every 10 mmHg 
reduction in systolic blood pressure.59 The review found that results were consistent across different 
levels of initial blood pressure, even in those with systolic blood pressure of <130 mmHg, and in people 
with and without prior CVD.59 Overall the evidence suggests that there is a proportional relationship 
between lower systolic blood pressure and improvements in CVD outcomes. There is strong evidence 
to support targeting of systolic blood pressure to <130 mmHg although lower is generally better and 
exact treatment targets should be decided on an individual basis depending on the clinical context and 
consideration of the benefits vs. harms. This evidence informed the development of the 2016 National 
Heart Foundation of Australia hypertension guideline which recommends a general target of systolic 
blood pressure <140 mmHg and a lower target of <120 mmHg in those at high absolute CVD if 
considered safe on an individual basis. 
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F u t u r e  d i r e c t i o n s  
Although we found little direct empirical evidence using data from Aboriginal and Torres Strait Islander 
populations in our evidence review, the importance of providing specific recommendations for 
Aboriginal and Torres Strait Islander peoples should be acknowledged. All Australian guidelines that 
made recommendations on absolute CVD risk assessment also provided specific recommendations for 
assessing and managing Aboriginal and Torres Strait Islander CVD risks. In addition to the clinical 
guidelines reviewed in this report, several other resources for improving Aboriginal and Torres Strait 
Islander cardiovascular health are available. ESSENCE outlines the essential services and care that 
should be accessible to Aboriginal and Torres Strait Islander people to prevent and manage CVD.51 In 
order to reduce the disparities in Aboriginal and Torres Strait Islander CVD morbidity and mortality, the 
ESSENCE standards focus on targeting the social determinants of health, improving access to affordable 
nutrition, and affirming the central role of primary health care for cardiovascular assessment and 
treatment. Each of the ESSENCE standards are grouped against ten targets for policy development and 
health system reform, rated by feasibility, and have an expected timeframe for implementation. The 
Better Cardiac Care measures for Aboriginal and Torres Strait Islander people is an Australian 
Government initiative set-up by the Australian Health Ministers' Advisory Council in 2014. The aim is 
to reduce cardiovascular morbidity and mortality by improving access to health services and 
management of CVD risk factors and treatment. The initiative outlines five priority areas for action, 
including early CVD risk assessment and management to improve primary prevention. While neither 
ESSENCE nor Better Cardiac Care provide clinical guidance, they set-out system-wide improvements 
that are needed to improve cardiac health and prevent Aboriginal and Torres Strait Islander CVD 
mortality and morbidity. These resources should be taken into account when updating and aligning 
recommendations in clinical guidelines.  
 
More empirical evidence is needed to inform Australian clinical guidelines and provide consistent 
messages regarding Aboriginal and Torres Strait Islander absolute CVD risk. The Cardiovascular Risk in 
Indigenous People study will involve the collation of data from six existing Australian cohorts from 
Northern Territory, Queensland and Western Australia, with data from an estimated 6,000 Aboriginal 
and Torres Strait Islander people. The aim of the study is to investigate the relationship between non-
traditional risk factors, such as abdominal obesity and metabolic disorders, and CVD outcomes, and to 
assess the accuracy of current CVD risk scores, and develop and improve CVD risk scores. There are 
limitations to this dataset including small sample sizes for validation, historical data and inconsistencies 
in data recording, limiting the transferability of these results. The Better Indigenous Risk stratification 
for Cardiac Health study aims to enroll 1,000 Aboriginal and Torres Strait Islander people from remote 
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and urban areas of Australia and 1,000 non-Indigenous participants.60 Information on traditional CVD 
risk factors will be collected in addition to data on emerging and novel risk factors including sleep 
quality, lipid profiles and pre-clinical CVD markers. Data collected in the study will be used to examine 
the association between these novel risk factors and Aboriginal and Torres Strait Islander CVD 
outcomes to improve CVD absolute risk assessment. It should be noted that it will take a considerable 
time for this study to produce results and the numbers will be too small on their own to be useful for 
recalibrating Aboriginal and Torres Strait Islander CVD risk scores. 
 
While these studies will provide valuable data sources for improving CVD risk assessment and 
management in Aboriginal and Torres Strait Islander peoples, including investigating CVD risk 
prediction, the extent to which the data will be able to resolve many of the outstanding issues is 
unclear, including validation of recalibrated risk scores and examining how early in life and how often 
CVD risk assessment should be done. This is because the number of events, even in the combined data, 
is relatively small. 
 
A framework is needed to provide large-scale data to allow regular and ongoing re-calibration and 
refinement of risk prediction, along the lines of those implemented internationally. In New Zealand, 
the PREDICT-CVD cohort includes electronic general practice data captured through integrated 
decision support software, with annual linkage to anonymised routine datasets including medication 
dispensing, pathology results, hospitalisations and deaths.61 The PREDICT-CVD data have been used to 
examine the levels of CVD risk factors and test the performance of the FRE in Māori, Pacific and Indian 
populations.61 Plans to link electronic general practice records in the Northern Territory with hospital 
and death data may provide an opportunity to obtain the large-scale, continuously recorded data 
needed for similar research in Australia.62 The MedicineInsight dataset which contains Australian 
general practice data from almost 4 million patients (~73,000 Aboriginal and Torres Strait Islander 
patients), could provide an additional valuable data source for improving Australian absolute CVD risk 
prediction (Aboriginal and Torres Strait Islander and non-Indigenous) but is not currently routinely 
linked with hospital and deaths data needed to identify CVD events.63 Infrastructure is needed to allow 
recommendations in clinical guidelines to be updated regularly as direct evidence from Aboriginal and 
Torres Strait Islander peoples becomes available.  
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Appendix A: Search strategy for the systematic review on the assessment of 
absolute CVD risk and treatment in Aboriginal and Torres Strait Islander people 
and Indigenous New Zealand populations  
We searched MEDLINE and Scopus (PROPSERO registration number: CRD42017079181), with searches 
were restricted to English language and to articles published since 2012 (date of the latest guideline). 
Search terms for each database are provided below. Titles and abstracts were screened to identify 
relevant publications. Full texts were then identified for the relevant publications and two researchers 
(EP and SP) independently assessed the publications against the selection criteria. Additional 
publications were identified through stakeholder engagement. Data were systematically extracted 
from the publications using data extraction templates.   
 
Inclusion criteria:  
 Related to assessing absolute CVD risk assessment and/or approaches for treating high 
absolute risk in Aboriginal and/or Torres Strait Islander people or Indigenous people in New 
Zealand.  
 Included participants without existing CVD, or participants with and without prior CVD but 
where the results were presented separately for these groups.  
 Included primary data  
Exclusion criteria: 
 Studies that only included pregnant women or children (<18 years old),  
 Studies that detailed the development or testing of electronic decision support tools 
 Studies that only reported on population profiles of CVD absolute risk. 
 
The quality of the included studies was assessed independently by two reviewers (LO and SP), with 
discrepancies resolved by discussion and by adjudication of a third reviewer (EP), using the Quality 
Assessment Tool for Observational Cohort and Cross-Sectional Studies from National Heart, Lung and 
Blood Institute. 
 
MEDLINE search terms: 
1. Cardiovascular OR "Heart disease" OR CVD OR "Coronary heart disease" OR CHD OR 
"cardiovascular system" OR "Cardiovascular Diseases"[Mesh] OR "cardiovascular 
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system"[MeSH Terms]  OR Stroke OR “Cerebrovascular disease*” OR “Myocardial 
infarction” OR MI OR “Ischaemic heart disease “ OR IHD  
2. "risk prediction*" OR "risk model*" OR "risk score*" OR "risk assessment*" OR "Models, 
Cardiovascular"[Mesh] 
3. “Early Medical Intervention” [MeSH] OR risk management [MeSH] OR “primary 
prevention” OR "Primary Prevention"[MeSH] OR “Preventive Health Services” [MeSH] OR 
"Cardiovascular Diseases/prevention and control"[MeSH Terms] OR "Coronary 
Disease/prevention and control"[MeSH] 
4. Indigenous OR Aboriginal OR  “Torres Strait Islander” OR Maori 
5. Australia OR “New Zealand” 
6. 1 AND (2 OR 3) AND 4 AND 5 
 
Scopus search terms: 
1. TITLE-ABS-KEY ( cardiovascular  OR  "Heart disease"  OR  cvd  OR  "Coronary heart 
disease"  OR  chd  OR  "cardiovascular system"  OR  "Cardiovascular Disease*"  OR  
"cardiovascular system"  OR  stroke  OR  "Cerebrovascular disease*"  OR  "Myocardial 
infarction"  OR  mi )  OR  TITLE-ABS-KEY ( "Ischaemic heart disease"  OR  ihd )   
2. (TITLE-ABS-KEY ( "risk prediction"  OR  "risk model*"  OR  "risk score*"  OR  "risk 
assessment*"  OR  "Models, Cardiovascular" ) OR   TITLE-ABS-KEY (“early medical 
intervention” OR “risk management” OR “primary prevention” OR “preventive Health 
Services” OR "Cardiovascular Diseases/prevention and control” OR "Coronary 
Disease/prevention and control”))AND  TITLE-ABS-KEY ( Indigenous  OR  Aboriginal  OR  " 
Torres Strait Islander" OR Maori )  AND  TITLE-ABS-KEY ( Australia OR “New Zealand” ) )  
AND  PUBYEAR  >  2010 
3. 1 AND 2 
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Appendix B: Search strategy for approaches to updating clinical guidelines 
MEDLINE, Scopus and the Cochrane Library were searched for studies published in English since 01 July 
2012 (date of last systematic review on this topic). Search terms for each database are provided below. 
We used the same selection criteria as was used in the systematic review published in 2012.17 
 
Inclusion criteria: 
 Evaluated one or more methods of updating (with or without monitoring) evidence-based 
clinical guidelines or recommendations, without restriction by health topic. 
 Assessed strategies for evaluating if clinical guidelines are out of date; for updating clinical 
guidelines; or for continuous monitoring and updating of clinical guidelines. 
Exclusion criteria: 
 Methodological handbooks and clinical guidelines updates.  
 
Titles and abstracts were screened to identify relevant publications. Full texts were then identified for 
the relevant publications and two researchers (AD and KM) independently assessed the publications 
against the selection criteria. Data extraction templates were used to systematically extract data from 
the relevant guidelines. 
 
MEDLINE search terms:  
1. Clinical practice guideline*[tw]   
2. Clinical guideline*[tiab]    
3. Guideline*[ti]     
4. Updat*[tw]     
5. Up to date[tw]     
6. (#1 OR #2) OR #3    
7. #5 OR #6     
8. #4 AND #7   
   
Cochrane Library search terms: 
1. Clinical practice guideline*’:ti, ab, kw  
2. Clinical guideline*    
3. Guideline*:ti     
4. (#1 OR #2 OR #3)    
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5. Update*     
6. Up to date     
7. (#5 OR #6)     
8. (#4 AND #7)    
 
Scopus search terms: 
1. (TITLE-ABS-KEY (‘clinical practice guideline*’ OR “Clinical guideline*”) AND TITLE 
(guideline*) AND TITLE-ABS-KEY (updat* OR “up to date”)) AND PUBYEAR > 2011 AND 
PUBYEAR <2018 
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Appendix C: Data extracted from Australian clinical guidelines on absolute CVD risk assessment and management  
The tables below contain information extracted from Australian clinical guidelines that include recommendations on absolute CVD risk assessment and 
management. Table 1 contains information related to recommendations on how absolute CVD risk should be assessed, including the age at which screening 
for CVD risk should start, clinical risk factors that indicate a person should be automatically considered to be at high risk of CVD regardless of their calculated 
absolute risk score, and how frequently people are recommended to have their absolute CVD risk assessed. Table 2 comprises information on 
recommendations related to management of absolute CVD risk, including the thresholds for commencing treatment, what treatments are recommended for 
those at moderate or high absolute risk of CVD, and treatment targets. 
 
Table C1: Summary of absolute CVD risk assessment as recommended relevant Australian clinical guidelines  
Guideline Age-range  
for screening  
Factors defining clinically 
determined high risk 
Risk score and calculation tools  Risk adjustments Frequency of recommended re-
assessment 
CVD-specific guidelines 
NVDPA Guidelines 
for the 
Management of 
Absolute 
Cardiovascular 
Disease Risk5 
Non-Indigenous 
Australians: 45-
74 
Aboriginal and 
Torres Strait 
Islander people: 
35-74  
 Diabetes and age >60 years 
 Diabetes with microalbuminuria 
 Moderate or severe chronic 
kidney disease (CKD) 
 Familial hypercholesterolaemia 
 Systolic ≥180 mmHg or diastolic 
≥110mmHg 
 Serum total cholesterol >7.5 
mmol/L 
 Aboriginal or Torres Strait 
Islander people aged more than 
74 years 
Australian absolute CVD risk 
calculator and charts 
www.cvdcheck.org.au, based on 
the FRE  
None explicitly 
recommended 
 
Consider treating 
Aboriginal and 
Torres Strait 
Islander people 
as high risk if they 
are moderate 
absolute risk  
 Low (<10%): every 2 years 
 Moderate (10-15%): every 
6-12 months 
 High (>15%): according to 
clinical context 
General guidelines 
The CARPA 
Standard 
Non-Indigenous 
Australians: 45-
74  
Has one or more of the following: 
 Diabetes AND kidney disease 
(urine Albumin/creatinine ratio 
Calculated using a colour- coded 
risk matrix adapted from the 
NVDPA guidelines and the New 
Add 5% to 
calculated risk for 
Aboriginal and 
 Low (<10%): every 2 years 
with Adult Health Check 
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Guideline Age-range  
for screening  
Factors defining clinically 
determined high risk 
Risk score and calculation tools  Risk adjustments Frequency of recommended re-
assessment 
Treatment 
Manual15 
Aboriginal and 
Torres Strait 
Islander people: 
20-74  
(ACR) >2.4 for males, >3.4 for 
females) 
 Diabetes AND age over 60 years 
 CKD (Estimated glomerular 
filtration rate (eGFR) less than 
45) 
 Persistent systolic ≥180mmHg 
OR diastolic >110mmHg OR 
total cholesterol ≥7.5mmol/L 
 75 years or older 
Zealand (NZ) Cardiovascular Risk 
Charts.  
Specific charts are provided for 
Aboriginal and Torres Strait 
Islander people. 
Torres Strait 
Islander people 
 Moderate (10-15%): every 
year 
 High (>15%): continue to 
consider high-risk and treat 
to target. Do not stop 
medications when targets 
reached. 
RACGP National 
guide to a 
preventive health 
assessment for 
Aboriginal and 
Torres Strait 
Islander people18 
35-74 years, 
general health 
screening 
recommended to 
commence from 
age 12 
Same as the NVDPA guidelines FRE None explicitly 
recommended 
Annually as part of annual 
health assessment. For those 
being treated with lifestyle 
interventions, review every two 
years in those at low risk and 
according to clinical context for 
those at moderate or high risk. 
Those being treated with 
preventative medications 
should be re-assessed 
according to clinical context.  
Therapeutic 
guidelines 
cardiovascular 
version 619 
Aboriginal and 
Torres Strait 
Islander people: 
35 years and 
over 
non-Indigenous: 
45 years and 
over 
As per NVDPA guidelines  Australian absolute CVD risk 
calculator and charts 
www.cvdcheck.org.au, based on 
the FRE 
  Low (<10%): Reassess 
absolute CVD risk every 2 
years 
 Moderate (10-15%): 
Reassess absolute CVD risk 
every 6-12 months 
Guidelines for 
preventive 
Aboriginal and 
Torres Strait 
Islander people 
As per NVDPA guidelines Australian absolute CVD risk 
calculator and charts 
 Every two years 
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Guideline Age-range  
for screening  
Factors defining clinically 
determined high risk 
Risk score and calculation tools  Risk adjustments Frequency of recommended re-
assessment 
activities in 
general practice20 
Australians: 35 
years and over 
non-Indigenous: 
45 years and 
over 
www.cvdcheck.org.au, based on 
the FRE 
Chronic Conditions 
Manual: 
Prevention and 
Management of 
Chronic Conditions 
in Australia21 
Aboriginal and 
Torres Strait 
Islander people: 
35 years and 
over 
non-Indigenous: 
45 years and 
over 
As per NVDPA guidelines Australian cardiovascular risk 
charts from the National Stroke 
Foundation 
For Aboriginal 
and/or Torres 
Strait Islander 
people, consider 
managing as 
though at a 
higher risk level 
Discussed in the context of 
hypertensive patients. 
 Low (<10%): Review 
absolute risk in 6-12 
months 
 Moderate (10-15%): 
Review absolute risk in 3-6 
months 
Patients with pre-diabetes: 
Assessed every 12 months  
Guidelines on related chronic conditions or risk factors 
Guideline for the 
diagnosis and 
management of 
hypertension in 
adults – 201624 
Aboriginal and 
Torres Strait 
Islander people: 
35 years and 
over 
non-Indigenous: 
45 years and 
over 
Without a known 
history of CVD or 
other co-
morbidities 
As per NVDPA guidelines  Australian absolute CVD risk 
calculator and charts 
www.cvdcheck.org.au, based on 
the FRE 
Add 5% to the 
calculated risk 
score for 
Aboriginal and 
Torres Strait 
Islander people 
No specific advice for 
reassessment of absolute CVD 
risk. 
If diagnosed with hypertension 
and:  
 At high absolute CVD risk 
(>15%): reviewed according 
to clinical context 
 At moderate absolute CVD 
risk (10-15%) and systolic 
130-139 mmHg or diastolic 
85-90 mmHg: blood 
pressure should be 
reviewed at 6 months 
 At low absolute CVD risk 
(<10%) and systolic 140-
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Guideline Age-range  
for screening  
Factors defining clinically 
determined high risk 
Risk score and calculation tools  Risk adjustments Frequency of recommended re-
assessment 
159 mmHg: blood pressure 
should be reviewed after 2 
months of lifestyle advice 
General practice 
management of 
type 2 diabetes25 
Not specifically 
stated 
As per NVDPA guidelines  The guidelines recommend 
calculating risk level using an 
evidence based tool: 
 NVDPA charts, 
www.cvdcheck.org.au 
 NZ Cardiovascular Risk charts, 
www.health.govt.nz/publicati
ons 
 Heart Foundation NZ, 
www.knowyournumbers.co.nz 
 
  Low (<10%): Review 
absolute risk every two 
years 
 Moderate (10-15%): 
Review absolute risk every 
6-12 months 
 High (>15%): Review 
absolute risk according to 
clinical context 
Chronic Kidney 
Disease 
Management in 
General Practice26 
Aboriginal and 
Torres Strait 
Islander people: 
35 years and 
over 
non-Indigenous: 
45 years and 
over 
Without existing 
CVD or other 
clinically 
determined high 
risk factors 
As per NVDPA guidelines  Australian absolute CVD risk 
calculator and charts 
www.cvdcheck.org.au, based on 
the FRE 
 Not discussed 
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Guideline Age-range  
for screening  
Factors defining clinically 
determined high risk 
Risk score and calculation tools  Risk adjustments Frequency of recommended re-
assessment 
Smoking, 
nutrition, alcohol, 
physical activity 
(SNAP): A 
population health 
guide to 
behavioural risk 
factors in general 
practice28  
Not discussed. As 
per NVDPA 2012 
Guidelines. 
As per NVDPA guidelines   www.cvdcheck.org.au, based 
on the FRE 
 Australian cardiovascular risk 
charts from the Australian 
Heart Foundation 
 Not discussed. As per NVDPA 
2012 Guidelines. 
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Table C2: Summary of the management of absolute CVD risk as recommended relevant Australian clinical guidelines 
Guideline Risk thresholds for 
commencing 
treatment 
Other conditions not already 
defined that may impact on 
treatment decisions 
Treatments recommended for 
those at moderate risk 
Treatments recommended for 
those at high risk 
Treatment targets 
CVD-specific guidelines 
NVDPA Guidelines 
for the Management 
of Absolute 
Cardiovascular 
Disease Risk5 
Generally if absolute 
risk of having a CVD is 
>15% over the next 5 
years  
 
Diabetes, CKD Lifestyle: appropriate, specific 
advice and support regarding 
diet and physical activity; 
appropriate advice, support 
and pharmacotherapy for 
smoking cessation. 
 
Medications: not routinely 
recommended. Consider 
blood pressure lowering 
and/or lipid lowering if 3-6 
months of lifestyle 
intervention does not reduce 
risk or if one or more applies: 
 Blood pressure 
persistently ≥160/100 
mmHg,  
 Family history of 
premature CVD 
 Specific population where 
FRE underestimates risk 
(e.g. Aboriginal and 
Torres Strait Islander 
peoples). 
Withdrawal of therapy could 
be considered for people who 
make profound lifestyle 
changes 
Lifestyle: frequent and 
sustained specific advice and 
support regarding diet and 
physical activity; appropriate 
advice, support and 
pharmacotherapy for smoking 
cessation; advice given 
simultaneously with blood 
pressure and lipid lowering 
drug treatment 
 
Medications: Treat 
simultaneously with lipid 
lowering and blood pressure 
lowering unless 
contraindicated or clinically 
inappropriate; Aspirin not 
routinely recommended; 
consider withdrawal of 
therapy for people who make 
profound lifestyle changes. 
Blood pressure:  
≤140/90 mmHg in general or 
people with CKD; ≤130/80 
mmHg in all people with 
diabetes; ≤130/80 mmHg in 
people with albuminuria. 
 
Lipids:  
Total cholesterol <4.0 
mmol/L; HDL-C ≥1.0 mmol/L; 
LDL-C <2.0 mmol/L; Non 
HDL-C <2.5 mmol/L; 
triglycerides <2.0 mmol/L. 
 
Lifestyle: smoking cessation; 
consume diet rich in 
vegetables and fruit, low in 
salt and saturated and trans 
fats; at least 30 mins 
moderate intensity physical 
activity on most or 
preferably all days of the 
week; limit alcohol intake to 
follow Australian guidelines. 
General guidelines 
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Guideline Risk thresholds for 
commencing 
treatment 
Other conditions not already 
defined that may impact on 
treatment decisions 
Treatments recommended for 
those at moderate risk 
Treatments recommended for 
those at high risk 
Treatment targets 
The CARPA Standard 
Treatment Manual15 
More than 15% 
chance of heart attack 
or stroke in the next 5 
years  
  Address the following risk 
factors: 
 Smoking 
 Overweight/obesity 
 Alcohol 
 Physical activity 
 High blood pressure 
 Diabetes 
 Abnormal blood fats 
 Kidney disease 
 Depression 
 Smoking cessation  
 Overweight/obesity: 
less saturated fats, salts; 
more physical activity; 
≤94cm waist for males, 
≤80cm waist for females 
 Limit alcohol intake to 
≤2 standard drinks/day 
 High blood pressure 
<130/80; ACEi 
recommended 
 Diabetes: aim for HbA1c 
53mmol/mol (≤7%); oral 
medicines for glucose 
control, often need 
insulin as well 
 Abnormal blood fats: 
monitor levels; treat to 
target; statin 
recommended 
 Kidney disease: monitor 
eGFR and urine ACR; 
target blood pressure 
<130/80; ACEi 
recommended 
 Depression: identify and 
treat 
 Aspirin recommended if 
CVD or diabetes 
RACGP National 
guide to a 
Pharmacotherapy 
recommended for 
 Obesity Lifestyle risk reduction advice 
for the following 
Lifestyle risk reduction advice 
same as moderate risk. 
 Smoking cessation 
 Healthy diet 
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Guideline Risk thresholds for 
commencing 
treatment 
Other conditions not already 
defined that may impact on 
treatment decisions 
Treatments recommended for 
those at moderate risk 
Treatments recommended for 
those at high risk 
Treatment targets 
preventive health 
assessment for 
Aboriginal and 
Torres Strait Islander 
people18 
 Low risk (<10%) 
with blood 
pressure 
persistently 
≥160/100 mmHg 
 Moderate risk 
(10-15%) after 
review and unless 
contraindicated 
 High risk (>15%) 
unless 
contraindicated 
 Family history of CVD 
before age 55 years in a 
mother, father, or sibling 
 Presence of albuminuria 
 Atrial fibrillation 
 Impaired fasting glucose 
intolerance 
 Socioeconomic hardship 
 Depression or other 
psychosocial stress 
 Excessive alcohol intake 
 Physical activity 
 Weight loss 
 Smoking cessation 
 Reduce salt to <4g/day 
 Diet rich in fruit and 
vegetables, whole grain 
cereals, nuts and seeds, 
legumes, fish, lean meat, 
poultry, low fat dairy 
products and limiting 
saturated and trans fat 
intake 
 Limit alcohol intake to ≤2 
standard drinks/day 
Pharmacotherapy 
 Review individual risk 
factor profile and 
recommend commencing 
a blood pressure lowering 
medication and/or lipid 
lowering medication 
unless contraindicated 
Pharmacotherapy 
 Recommend commencing 
both a blood pressure 
lowering medication and 
lipid lowering medication 
regardless of risk factor 
levels unless 
contraindicated 
 Aspirin is not routinely 
recommended 
 Reduce salt to >4g/day 
 Limit alcohol intake to 
≤2 standard drinks/day 
Therapeutic 
guidelines 
cardiovascular 
version 619 
 Moderate risk 
(10-15%) if 3 to 6 
months of 
behavioural risk 
modification does 
not reduce risk; 
blood pressure 
persistently 
≥160/100 mmHg; 
 Blood pressure 
persistently ≥160/100 
mmHg 
 Family history of 
premature CVD 
 Specific population 
where FRE 
underestimates risk 
Lifestyle: appropriate, specific 
advice and support regarding 
diet and physical activity; 
appropriate advice, support 
and pharmacotherapy for 
smoking cessation. 
 
Medications: not routinely 
recommended. Consider 
 Frequent and sustained 
specific advice and 
support regarding diet 
and physical activity 
 Same smoking cessation 
advice as moderate risk 
 Treat simultaneously with 
blood pressure-lowering 
and lipid-modifying 
None given. 
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Guideline Risk thresholds for 
commencing 
treatment 
Other conditions not already 
defined that may impact on 
treatment decisions 
Treatments recommended for 
those at moderate risk 
Treatments recommended for 
those at high risk 
Treatment targets 
family history of 
premature CVD; 
specific 
population where 
FRE 
underestimates 
risk 
 High risk (>15%) 
blood pressure lowering 
and/or lipid lowering if 3-6 
months of lifestyle 
intervention does not reduce 
risk or if one or more applies: 
 Blood pressure 
persistently ≥160/100 
mmHg,  
 Family history of 
premature CVD 
 Specific population where 
FRE underestimates risk 
(e.g. Aboriginal and 
Torres Strait Islander 
people). 
 Withdrawal of therapy 
could be considered for 
people who make 
profound lifestyle 
changes 
therapy unless 
contraindicated or 
clinically inappropriate 
 Aspirin not routinely 
recommended 
 
Guidelines for 
preventive activities 
in general practice20 
 Low risk (<10%) if 
blood pressure 
persistently over 
160/100 mmHg 
 Moderate risk 
(10-15%): if 
systolic is 140-159 
mmHg or diastolic 
is 90-99 mmHg; 
blood pressure 
persistently over 
  Provide lifestyle advice 
 Consider 
pharmacotherapy if 
systolic 140-159 mmHg or 
diastolic 90-99 mmHg. If 
systolic 130-139 mmHg or 
diastolic 85-89mmHg, 
review blood pressure in 
six months 
 Offer pharmacotherapy 
simultaneously with 
 Provide intensive lifestyle 
advice 
 Commence 
pharmacotherapy 
(simultaneously with lipid 
therapy unless 
contraindicated) 
 Ask questions about 
symptoms of transient 
ischaemic attacks 
 Blood pressure ≤140/90 
mmHg in adults without 
CVD, or lower (systolic 
<120 mmHg) in some 
individuals who tolerate 
more intensive 
treatment and those 
with CKD 
 Blood pressure  ≤130/80 
mmHg in people with 
diabetes or 
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Guideline Risk thresholds for 
commencing 
treatment 
Other conditions not already 
defined that may impact on 
treatment decisions 
Treatments recommended for 
those at moderate risk 
Treatments recommended for 
those at high risk 
Treatment targets 
160/100 mmHg; 
family history of 
premature CVD; 
specific 
population where 
FRE 
underestimates 
risk 
 High risk (>15%) 
lifestyle intervention if 
blood pressure 
persistently ≥160/100 
mmHg or if family history 
of premature CVD or 
specific population where 
FRE underestimates risk 
 If atrial fibrillation, 
determine cause and 
treat according to 
cardiovascular and 
thromboembolic risk 
 
microalbuminuria or 
macroalbuminuria 
Chronic Conditions 
Manual: Prevention 
and Management of 
Chronic Conditions 
in Australia21 
Discussed in the 
context of 
hypertension 
 Low risk (<10%): if 
systolic ≥ 150 
mmHg or diastolic 
≥90 mmHg 
 Moderate risk 
(10-15%): if 
systolic ≥ 140 
mmHg or diastolic 
≥90 mmHg 
 High risk (>15%) 
 Depression 
 Socioeconomic 
deprivation 
 Diabetes 
 Aboriginal or Torres Strait 
Islander people 
 Lifestyle modification 
 Manage blood pressure 
 Manage associated 
conditions and reassess 
absolute CVD regularly 
 Start drug treatment if 
systolic ≥ 140 mmHg or 
diastolic ≥90 mmHg 
In addition to treatments for 
moderate risk, start drug 
treatment immediately 
Treatment targets in the 
context of other conditions 
only discussed 
Guidelines on related chronic conditions or risk factors 
Guideline for the 
diagnosis and 
management of 
hypertension in 
adults – 201624 
 Low risk (<10%) if 
blood pressure 
persistently 
≥160/100 mmHg 
 Moderate risk 
(10-15%): if 
persistent blood 
pressure ≥140 
  Provide lifestyle advice 
 For patients with blood 
pressure persistently 
≥160/10 mmHg; 
persistent blood pressure 
≥140 mmHg systolic 
and/or ≥90 mmHg 
diastolic; family history of 
 Provide lifestyle advice 
 Start immediate drug 
treatment 
 In selected high 
cardiovascular risk 
populations where a 
more intense treatment 
can be considered, 
aiming to a target of 
<120 mmHg systolic can 
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Guideline Risk thresholds for 
commencing 
treatment 
Other conditions not already 
defined that may impact on 
treatment decisions 
Treatments recommended for 
those at moderate risk 
Treatments recommended for 
those at high risk 
Treatment targets 
mmHg systolic 
and/or ≥90 
mmHg diastolic; 
blood pressure 
persistently 
≥160/100 mmHg; 
family history of 
CVD; or Aboriginal 
or Torres Strait 
Islander people 
 High risk (>15%) 
premature CVD; or 
Aboriginal or Torres Strait 
Islander people, 
antihypertensive therapy 
should be started 
 Aspirin not recommended 
for CVD prevention in 
patients with 
hypertension at low-
moderate risk 
improve cardiovascular 
outcomes 
General practice 
management of type 
2 diabetes25 
 Low risk (<10%) if 
blood pressure 
persistently 
>160/100 mmHg 
 Moderate risk 
(10-15%): if 3-6 
months of 
lifestyle 
intervention does 
not reduce risk; 
blood pressure 
persistently 
>160/100 mmHg; 
family history of 
premature CVD; 
or specific 
population where 
FRE 
underestimates 
risk 
 Lifestyle: appropriate, specific 
advice and support regarding 
diet and physical activity; 
appropriate advice, support 
and pharmacotherapy for 
smoking cessation. 
 
Medications: not routinely 
recommended. Consider 
blood pressure lowering 
and/or lipid lowering if 3-6 
months of lifestyle 
intervention does not reduce 
risk or if one or more applies: 
 Blood pressure 
persistently ≥160/100 
mmHg,  
 Family history of 
premature CVD 
 Frequent and sustained 
specific advice and 
support regarding diet 
and physical activity 
 Same smoking cessation 
advice as moderate risk 
 Treat simultaneously with 
lipid-lowering and blood 
pressure-lowering drug 
treatment unless 
contraindicated or 
clinically inappropriate 
 Aspirin is not routinely 
recommended 
 Consider withdrawal of 
therapy for people who 
make profound lifestyle 
changes 
Moderate risk: 
 Total cholesterol <4.0 
mmol/L 
 High density lipoprotein 
cholesterol ≥1.0 mmol/L 
 Low density lipoprotein 
cholesterol <2.0 mmol/L 
 NonHDL-C <2.5 mmol/L 
 Triglicerides <2.0 
mmol/L 
 Smoking cessation 
 Consume diet rich in 
vegetables and fruit, 
low in salt and saturated 
and trans fats 
 At least 30 min physical 
activity on most or 
preferably every day of 
the week 
 Limit alcohol intake 
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Guideline Risk thresholds for 
commencing 
treatment 
Other conditions not already 
defined that may impact on 
treatment decisions 
Treatments recommended for 
those at moderate risk 
Treatments recommended for 
those at high risk 
Treatment targets 
 High risk (>15%)  Specific population where 
FRE underestimates risk 
(e.g. Aboriginal and 
Torres Strait Islander 
peoples). 
 Withdrawal of therapy 
could be considered for 
people who make 
profound lifestyle 
changes 
High risk: 
 ≤140/90 mmHg in 
general or people with 
CKD 
 ≤130/80 mmHg in all 
people with diabetes 
 ≤130/80 mmHg if 
microalbuminuria or 
macroalbuminuria 
Chronic Kidney 
Disease 
Management in 
General Practice26 
Guidelines 
recommend 
pharmacological 
management 
strategies (if 
indicated) based on 
the patient’s risk level 
and clinical judgement 
(e.g. high risk require 
more intensive 
intervention and 
follow up) 
  Basic lifestyle advice 
 Pharmacotherapy not 
discussed by absolute 
CVD risk categories 
 Basic lifestyle advice 
 Pharmacotherapy if blood 
pressure is above target 
level (≥140/90 mmHG). 
Pharmacotherapy is not 
discussed by absolute 
CVD risk categories 
Treatment targets in the 
context of CKD only 
discussed  
Smoking, nutrition, 
alcohol, physical 
activity (SNAP): A 
population health 
guide to behavioural 
risk factors in 
general practice28 
Not discussed. As per 
NVDPA 2012 
Guidelines. 
 Not discussed. As per NVDPA 
2012 Guidelines. 
Not discussed. As per NVDPA 
2012 Guidelines. 
Not discussed. As per NVDPA 
2012 Guidelines. 
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Appendix D: Flow chart showing selection of studies for the evidence review for 
aligning the guidelines 
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Appendix E: Flow chart showing selection of studies for the review of approaches 
for updating clinical guidelines 
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Appendix F: Data extracted from studies included in the review of approaches for updating clinical guidelines 
The two tables below contain information extracted from the studies identified in the literature search of approaches for updating clinical guidelines.  
 
Table F1: Overview of included studies 
Study Study Type Objective Sample Health Topic Country 
Articles identified in 2012 systematic review by Martinez Garcia et al.  
Shekelle et 
al. 200164 
Prospective, not comparison 
study 
Evaluate if clinical guidelines 
out of date 
17 clinical 
guidelines 
Several USA 
Bosquet et 
al. 200365 
Prospective, not comparison 
study 
Evaluate if clinical guidelines 
out of date 
1 clinical guideline PET scanning in cancer France 
Gartlehner et 
al. 200443 
Prospective, comparison 
study 
Evaluate if clinical guidelines 
out of date 
6 topics Prevention topics USA 
Nunes et al. 
200966 
Prospective, not comparison 
study 
Evaluate if clinical guidelines 
out of date 
1 clinical guideline Obesity UK 
Eccles et al. 
200242 
Prospective, comparison 
study (development vs 
updating) 
Compare updating process 2 clinical guidelines Angina and asthma in adults UK 
Newton et al. 
200667 
Prospective, not comparison 
study 
Updating and adapting clinical 
guideline 
1 clinical guideline Posttraumatic Stress Disorder Australia 
Parmelli et 
al. 201168 
Prospective, comparison 
study (development vs 
updating) 
Updating  15 
recommendations 
Anticancer drug for breast, 
colorectal and lung cancer 
Italy 
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Study Study Type Objective Sample Health Topic Country 
Johnston et 
al. 200369 
Prospective, not comparison 
study 
Continuous monitoring and 
updating strategy ('living' 
guidelines) 
20 clinical 
guidelines 
Cancer Canada 
Articles identified by systematic review 
Dhaliwal et 
al. 201470 
Prospective, not comparison 
study 
Updating clinical guidelines 68 RCTs Critical care nutrition Canada 
Shekelle et 
al. 201245 
Methodology Review Guideline development 
methods 
NA Various USA 
Martinez 
Garcia et al. 
201544 
Prospective, comparison 
study  
Evaluate strategies to update 
clinical guidelines 
4 clinical guidelines Various Spain 
Vernooij et 
al. 201440 
Systematic review Identify guidance for updating 
clinical guidelines 
35 handbooks NA Spain 
Zamborlini et 
al. 201771 
Prospective, comparison 
study 
Strategies for detecting 
evidence for updating clinical 
guidelines 
11 conclusions Breast cancer Netherlands 
Becker et al. 
201439 
Systematic review Updating clinical guidelines 7 articles, 47 
manuals 
Various Germany 
Agbassi et al. 
201441 
Methodology Review Describe and validate strategy 
for updating clinical 
guidelines 
2011: 109 
documents, 2012: 
88 documents 
NS Canada 
Uhlig et al. 
201647 
Review Updating clinical guidelines NA Kidney disease USA 
Articles detailing methodological and software tools 
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Study Study Type Objective Sample Health Topic Country 
Zhu et al. 
201372 
Methodological Automatic extraction of 
information from clinical 
guidelines 
177 
recommendations 
NS China 
Bittl et al. 
201773 
Statistical methods Evaluate Bayesian analysis for 
updating of clinical guidelines 
3 clinical examples Diabetes and coronary artery 
disease 
USA 
Vandvik et al. 
201349 
Methodological Address problems in 
development, dissemination, 
and updating of trustworthy 
clinical practice guidelines  
NA NA Norway 
Iruetaguena 
et al. 201346 
Methodological Updating bibliography 
references using algebraic 
scoring method 
40 clinical 
guidelines 
Several topics Spain 
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Table F2: Stages of the strategies 
Author  & year Update method/tool Evidence search strategy Search/tool performance Changes to guidelines Resource use (time) 
Articles identified in 2012 systematic review by Martinez Garcia et al. 
Shekelle et al. 200164 Validity of clinical 
guidelines based on 
search and survey with 
clinical experts 
Restricted search 5 key 
medical journals and key 
specialty journals. Reviews, 
editorials, commentaries. 
Additional search in NGC 
and web sites of clinical 
guidelines publishing 
organizations. Surveyed 
experts by mail 
2.9% (208 articles reviewed 
from 7.150 articles initially 
identified) 
76.5% of the guidelines 
needed updating 
NS 
Bosquet et al. 200365 Search and 
consultation with 
original working group 
Exhaustive search 
MEDLINE, EMBASE, SBU & 
APM web sites 
45.2% (118 references 
submitted to the working 
group from 261 references 
initially identified) 
NA NS 
Gartlehner et al. 200443 Comparative search 
strategies 
Modified Shekelle et al 
2001 & Exhaustive search 
MEDLINE, The Cochrane 
Library Reviews, meta-
analysis, RCTs. Surveys to 
national or international 
experts 
Modified Shekelle: 2.6% (36 
eligible studies from 1,382 
citations initially identified), 
Exhaustive: 1.2% (45 eligible 
studies from 3,687 initially 
identified) 
NA NS 
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Author  & year Update method/tool Evidence search strategy Search/tool performance Changes to guidelines Resource use (time) 
Nunes et al. 200966 Search and review of 
new clinical guidelines 
Restricted search 
Guidelines 
28% (seven guidelines 
reviewed from 25 guidelines 
initially identified) 
No recommendations 
needed to be updated 
NS. Less time 
required to perform 
update than 
perform an 
exhaustive search 
Eccles et al. 200242 Comparison of 
development and 
updating process 
Exhaustive search 
MEDLINE, EMBASE, The 
Cochrane Library 
1.0% for each guideline Recommendations 
remained unchanged.  
NS. Cited as time 
consuming 
Newton et al. 200667 Compare updating 
method with original 
development process, 
adapt to local context 
Exhaustive search NS 0.2% (43 studies included 
from 19,423 citations initially 
identified) 
Integrating a qualitative 
and quantitative data on 
the prior review and 
developing 
recommendations 
9 months to update 
11 research 
questions and 
develop 7 new 
questions 
Parmelli et al. 201168 Compare updating 
method with original 
development process 
Exhaustive search 
MEDLINE, EMBASE, central 
and databases for 
conference (ASCO) SRs, 
meta-analysis, RCTs 
3.5% (24 papers included 
from 686 records initially 
screened) 
6/15 recommendations 
updated. Classified 
strength of 
recommendation in 4 
levels: strong positive, 
weak positive, weak 
negative and strong 
negative. Voted by 
experts in meeting 
8 months 
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Author  & year Update method/tool Evidence search strategy Search/tool performance Changes to guidelines Resource use (time) 
Johnston et al. 200369 Monitoring strategy Exhaustive search MEDLINE 
(monthly), CancerList 
(monthly), HealthStar 
(monthly), The Cochrane 
Library (quarterly) 
Guidelines, SRs, RCTs 
Additional search in key 
journals and proceedings 
meeting, Notifications by 
DSG members 
23.75% (19 citations with 
impact on recommends from 
80 citations initially 
identified) 
Clinical recommendations 
were changed in in 30% of 
the guidelines 
NS 
Articles identified by systematic review 
Dhaliwal et al. 201470 Review of updated 
2013 clinical guidelines 
which are based on 
RCTs 
NS 68 new RCTs identified since 
the 2009 clinical guidelines 
10 new sections or clinical 
topics. Of the old clinical 
topics, 3 
recommendations were 
upgraded, 4 were 
downgraded, and 27 
remained the same 
NS 
Shekelle et al. 201245 Discussion about 
developing guidelines 
NS NA NA NA 
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Author  & year Update method/tool Evidence search strategy Search/tool performance Changes to guidelines Resource use (time) 
Martinez Garcia et al. 
201544 
Comparative search 
strategies 
Exhaustive and restrictive 
PubMed Clinical Queries 
for MEDLINE, PLUS 
(McMaster Premium 
Literature Service) 
database. 
69 references identified by 
exhaustive strategy/18 (or 
26.1%) references identified 
by PLUS strategy / 4486 
references initially retrieved 
Exhaustive strategy: 25 
recommendations/ 
Restrictive strategy: 18 
and 17/ PLUS strategy: 10 
recommendations (40%) 
Restrictive search: 
174hr/ PLUS search: 
28hr 
Vernooij et al. 201440 Updating guidance 
provided by clinical 
guidelines handbooks 
Exhaustive MEDLINE, 
Guidelines international 
network, US National 
Guidelines Clearinghouse, 
institutions that use 
handbooks in previous 
international survey 
35 handbooks (initially 1,992 
records identified) 
NA NS 
Zamborlini et al. 201771 Knowledge model 
(Transition-based 
Medical 
Recommendation 
model) for detecting 
new evidence 
NS Average of 32.6% recall, 
1145.18 papers, using 
semantic distance. Increasing 
to average 80.9% recall, 
885.45 papers, using the 
knowledge model 
NA NS. High human-
intervention cost 
Becker et al. 201439 Evaluate when and 
how to update 
guidelines; develop 
procedure for updating 
Exhaustive MEDLINE, 
Embase, the Cochrane 
Methodology Register 
7 full-text reports, 47 
manuals; developed 
systematic monitoring 
system and schedule 
updating process 
NA NS 
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Author  & year Update method/tool Evidence search strategy Search/tool performance Changes to guidelines Resource use (time) 
Agbassi et al. 201441 Use of document 
assessment and review 
(DAR) strategy 
NS 2011: 109 documents 
assessed/ 2012: 88 
documents assessed 
2011 assessment: 15 
urgent and high-priority 
reviews (52%) resulted in 
an endorsement, eight 
(28%) rewritten to correct 
or update the 
recommendations, six 
(21%) archived with no 
further action. 2012: 88 
total documents assessed; 
15 (17%) archived, 32 
(36%) deferred, 3 (3%) 
considered special cases, 
38 (43%) prioritized for 
review 
median time 167 
days (range, 18-358 
days) 
Uhlig et al. 201647 Review of updating 
methods 
NS NA Recommends that KDIGO 
move to dynamic 
updating (i.e 'living 
guidelines') 
NS 
Articles detailing methodological and software tools 
Zhu et al. 201372 Rule-based 
information extraction 
system 
NS Rule based method on test 
data set achieves 71.75% f-
measure for patient state 
annotation and 81.96% f-
measure for action 
annotation 
NS NS 
Bittl et al. 201773 Bayesian analysis NS Validated by 3 examples NS NS 
Vandvik et al. 201349 Online software app 
(MAGICapp) 
NS NS NS NS 
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Author  & year Update method/tool Evidence search strategy Search/tool performance Changes to guidelines Resource use (time) 
Iruetaguena et al. 201346 Scoring algorithm Restricted National 
Guideline Clearinghouse, 
Entrez Utilities Web 
Services, MEDLINE 
Method had a 91.9% finding 
average, increasing to 95.4% 
if focused on RCTs. 
None NS 
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Appendix G: Flow-chart for determining the type and scope of a guideline 
update39 
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Appendix H: Six-item document assessment tool41 
 
                        Document Assessment Tool 
Number and title of document   
Current Report Date  
Last Literature Search Date  
Date Assessed   
Research coordinator  
Outcome (for internal use)  
Instructions.  For each document, please respond YES or NO to all the questions below.  Provide an 
explanation of each answer as necessary. 
1. Is the document still relevant (clinically or to the cancer care system as a 
whole in some way)? 
 
2. Should full assessment and review of this document be deferred until next 
year? 
Consider YES if:    
 The document is less than three years old, and there is no reason to 
doubt the recommendations   
 The document is between three and five years old, and a justification 
can be provided as to why the recommendations can be considered 
trustworthy for another year 
 
3. Do the questions and search criteria as they are in the document address 
current needs,  such that an updated literature search would be useful and 
identify relevant evidence?  
Consider NO if:  
  The standard of care has shifted significantly since the last version of 
the document, such that the questions only address the topic in part 
 There are new, significant options (for treatment, diagnosis, etc.) 
available that are not covered by the current questions, such that new 
questions would need to be added to the document  
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 In general, if you believe that for the document to still be useful it will 
have to substantially be rewritten 
 The document has been repeatedly deferred, and is now older than 
five years 
4. Does the document have an impact on access to care (that is, are decisions 
about access or payment for care made by the Ministry, CCO, or other 
organizations based on the recommendations in this document)? 
Consider YES if:    
 Ministry funding decisions have been, are, or will be made on the 
basis of this document   
  An indication for a chemotherapy regimen was funded, or rejected, 
based on the document 
 Case by case review or out of country requests are known to be 
decided based on the document  
 Funding for some screening, diagnostic, staging or treatment 
procedure was or is determined 
 
5. Is there known evidence that has been published since this document’s last 
literature search (see above) that would result in significant changes to the 
recommendations? 
 
 
6. Should this document be taken off the website while it awaits full review, 
or can it be left there with an “IN REVIEW” watermark?  
Consider YES if:    
 If followed, even in error, the recommendations have the potential to 
cause harm to patients. 
 
Please list any additional factors that should be considered in prioritizing this document for review: 
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Appendix I: Four-item document review tool41 
                                 PEBC Document Review Tool 
Number and title of document 
under review 
 
Current Report Date  
Clinical Expert  
Research Coordinator  
Date Assessed  
Approval Date and Review 
Outcome (once completed) 
 
Original Question(s): 
 
Target Population: 
 
Study Section Criteria: 
 
Search Details:  
 
Brief Summary/Discussion of New Evidence: 
 
Clinical Expert Interest Declaration: 
 
Instructions.  Instructions.  For each document, please respond YES or NO to all the questions 
below.  Provide an explanation of each answer as necessary. 
1. Does any of the newly identified 
evidence, on initial review, contradict 
the current recommendations, such 
that the current recommendations 
may cause harm or lead to 
unnecessary or improper treatment if 
followed?   
 
2. On initial review,  
a. Does the newly identified 
evidence support the existing 
recommendations?  
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b. Do the current 
recommendations cover all 
relevant subjects addressed 
by the evidence, such that no 
new recommendations are 
necessary?   
3. Is there a good reason (e.g., new 
stronger evidence will be published 
soon, changes to current 
recommendations are trivial or 
address very limited situations) to 
postpone updating the guideline?  
Answer Yes or No, and explain if 
necessary:  
 
4. Do the PEBC and the DSG/GDG 
responsible for this document have 
the resources available to write a full 
update of this document within the 
next year? 
 
Review Outcome  
DSG/GDG Approval 
Date 
 
DSG/GDG 
Commentary 
 
 
